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New Zealand has one of the highest rates of colorectal cancer (CRC) in the world. 
Current strategies to diagnose CRC, including population level stool-based 
screening, are flawed due to poor sensitivity in early disease and limited 
participation. Patients have expressed a preference for a blood-based test, or ‘liquid 
biopsy’, if it were available. A liquid biopsy that has parity with, or outperforms 
current stool based screening would likely lead to earlier diagnosis of CRC and 
improved patient outcomes. Extracellular Vesicles (EVs) are produced in abundance 
by CRC cells, their contents also reflect their parent cell of origin. microRNA 
(miRNA) are small non-coding RNA molecules, which are dysregulated in CRC cells 
compared to normal cells. Identifying EV miRNA in the bloodstream of early stage 
CRC patients that are sufficiently different from healthy patients may enable 
identification of CRC from a liquid biopsy. Our study examined four miRNAs, miR-
19a, miR-23a, miR-183 and miR-1246, in both tumour tissue and plasma EVs that 
have previously been reported as dysregulated in CRC.  
miRNA expression of the candidate miRNAs was in examined in CRC tumour tissue 
vs normal colonic mucosa, and in plasma EVs of stage I and II CRC patients vs healthy 
controls, by RT-qPCR. Changes in expression in tissue were assessed to establish if 
they would translate to circulating EVs. Furthermore, any differences between the 
miRNA expression in plasma EVs were examined to assess for a capacity to 
differentiate early stage CRC patients from healthy controls and be useful as a liquid 
biopsy biomarker in CRC. 
From our results, miR-1246 and miR-183 were significantly overexpressed in 
tumour tissue compared to normal colonic mucosa. However, neither miRNA was 
consistently expressed in the circulating EVs. In the plasma analysis, miR-19a was 
significantly downregulated in EVs of CRC patients. It demonstrated significant 
differences even when stage I patients alone were compared against controls and it 
also had superior sensitivity to CEA in our cohort. This appears to be the first study 
to document a significant decrease in miR-19 in the EVs of early stage CRC patients. 
From our results, significant variance from the current literature was seen. Some 
possible factors for this variance may include differences in methodology and 
control selection.  
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Although, plasma EV miRNA display great promise as liquid biopsy biomarkers, 
there are a number of challenges in identifying a marker specific for CRC. 
Standardisation of methodology may help identify candidate miRNAs that offer the 
greatest potential. Finding a liquid biopsy biomarker for CRC that is equally 
effective, or outperforms, current faecal-based methods would likely increase 
uptake in screening. The subsequent effects would include decreased healthcare 
costs due to earlier diagnoses of CRC with improved patient outcomes for the 
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Chapter 1: Introduction 
1.1 Colorectal cancer 
Colorectal cancer (CRC) is a significant health issue, both internationally and in New 
Zealand. Globally, CRC is the third most common cancer with 1.8 million new cases 
diagnosed annually (1). Additionally, it is the second leading cause of cancer related 
mortality with 881,000 deaths estimated in 2018 (1). A decline in both incidence 
and mortality has been observed in some high-income countries (2), however the 
global burden of CRC is expected to increase significantly in coming decades. Given 
demographic projections, in just over a decade it is predicted that there will be an 
increase to more than 2.2 million new CRC diagnoses and 1.1 million deaths by 2030 
(3). 
New Zealand and Australia have some of the highest rates of CRC in the world (1). 
International trends are reflected in New Zealand where CRC is the second most 
common cancer after non-melanoma skin cancer, with approximately 3200 new 
cases diagnosed and 1200 deaths annually (4). Although, overall population rates of 
CRC have started to decline, it still places significant resource demands on our 
health system. Due to both population growth and aging, the numbers of new CRC 
diagnoses in New Zealand are likely to increase (4). Cases of CRC are forecast to 
increase by approximately 26% by the year 2026. This will likely lead to a 
proportional increase in demand for resources required for the diagnosis, treatment 
and follow up of CRC patients such as colonoscopy, surgery, chemotherapy, 
radiotherapy and outpatient appointments (4). The predicted yearly costs for CRC 
is expected to rise from $83.6 million in 2014 to $100 million in 2026 (4). As less 
intensive treatments are required for CRC if diagnosed at an earlier stage, measures 
that help increase the rate of diagnosis of early stage CRC may help to mitigate some 
of these expected cost increases. 
One of the most important predictors of survival in CRC is the extent of disease at 
diagnosis. The most widely used classification to quantify the extent of CRC is the 
tumour, nodes and metastases (TNM) classification (5). This measures the depth to 
which the tumour has invaded the bowel wall (T), presence and number of involved 
lymph nodes (N) and the presence of distant metastases (M) (see supplementary 
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Table S1 for further detail on TNM staging in CRC). In general, adjuvant or 
neoadjuvant treatments, in the form of chemotherapy and radiotherapy are 
reserved for patients with more advanced CRC. For the majority of patients 
diagnosed at a very early stage, surgery alone will be sufficient. In addition to 
requiring less intensive treatment, lower TNM stage is significantly associated with 
a benefit for most clinical outcomes including, lower rates of local or distant 
recurrence, improved disease free and overall survival (6-8).  
Early diagnosis is key to reducing CRC related mortality (9). Five-year survival for 
stage I colon cancer is 80%, which drops to 6% for stage IV disease (Table 1; 10). 
Prior to the introduction of a bowel-screening programme, New Zealand has lower 
rates of detection of early stage CRC when paralleled to some other comparable 
health systems that have established screening programmes. Stage I colon cancer 
only makes up 12% of diagnosed cases in New Zealand, in the UK rates of stage I 
diagnoses have been reported as high as 18% (4, 11). The proportion of stage IV 
disease for both colon (19%) and rectal (24%) cancers are higher in New Zealand 
compared to Australia (17-19%) and the UK (18%; 4, 11). This data further 
demonstrates that any strategies which aid earlier diagnosis of CRC should improve 


















Stage II 1139 (27%) 71% 





228 (5%)    
Stage IV 991 (24%) 6% 271 (19%) 10% 
Unknown 297 (7%)  64 (5%)  
Total 4193 (100%)  1401 (100%)  
Table 1- Colon and rectal cancer rates of diagnosis by stage (4) and five-year survival 
by stage (10) in New Zealand. (N1 = Metastasis in 1-3 regional lymph nodes, N2 = 
metastasis in 4 or more regional lymph nodes, NOS = not otherwise specified).  
The PIPER project included 5667 patients from across New Zealand over a 3 year 
period. It provides an insight into the landscape for CRC in New Zealand prior to the 
introduction of screening. The average ages for colon and rectal cancer were 67.9 
and 71.4 years respectively (12).  In the total recorded population, 75% were 
diagnosed with colon cancer and 25% with rectal cancer (12). With regard to 
ethnicity, 8% were Māori, higher proportions of metastatic disease at diagnosis are 
observed in Māori and Pacific populations. Rates of diagnosis for stage IV colon 
cancer being 32% and 35%, and for rectal cancer being 29% and 22% for Māori and 
Pacific patients, respectively (4). In non-Māori, non-Pacific patients the rates of 
metastatic disease at diagnosis were 23% and 18% for colon and rectal cancer 
respectively. The emergency department (ED) was the initial mode of presentation 
for 34% of patients with colon cancer, which is again higher for Māori (44%) and 
Pacific patients (51%). In contrast, only 20% of CRC patients are diagnosed through 
an emergency presentation in the UK (13). Methods that aid in the earlier detection 
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of CRC that are easily accessible in a primary care setting may contribute to 
decreased rates of metastatic and emergency presentations of CRC. This may 
contribute to decreasing the overall morbidity and mortality of CRC in the 
population and addressing inequalities in healthcare. 
1.1.1 Presentation and diagnosis of colorectal cancer 
Currently, a diagnosis of CRC is made following symptomatic presentation, due to 
the bowel-screening programme, or as an incidental finding during investigations 
performed for unrelated reasons. Symptoms include weight loss, change in bowel 
habit, and perirectal bleeding; however, patients are often asymptomatic at early 
stages of the disease (14). Colonoscopy is the gold standard investigative and 
diagnostic tool in CRC. Patients in New Zealand currently have access to endoscopy 
through surveillance if they are at increased risk, if they are symptomatic of CRC or 
if they have a positive bowel-screening test.  
During colonoscopy, any suspicious precancerous polyps are removed, and should 
a cancer be found, biopsies can be taken for histological evaluation. Despites it’s 
obvious utility, colonoscopy has some limitations and disadvantages including: 
extensive pre-procedure preparation, patient discomfort, and high healthcare costs 
that hinder its universal application as a screening tool (15). Patients who undergo 
polypectomy may occasionally develop post-polypectomy haemorrhage, including 
from extremely low risk lesions that would be unlikely to ever cause harm, and 
which would not have been seen by other investigative modalities (16). New 
Zealand data on colonoscopy complications show a rates of post-colonoscopy 
bleeding requiring hospital presentation and perforation of 0.79% and 0.12% 
respectively (17). 
Ideally, a colonoscopy would only be performed on patients that stand to benefit 
from the procedure. However, due to its nature as an investigative tool, there are a 
significant number of entirely normal colonoscopies performed. Data from the 
National Bowel Cancer Screening Programme pilot study states that 45% of positive 
screening tests result in an entirely normal colonoscopy (17). These patients are 
unnecessarily exposed to some of the risks of colonoscopy in addition to consuming 
a limited resource. Any diagnostic test for CRC with increased specificity compared 
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to current methods may help decrease the number of these unnecessary 
colonoscopies and assist in more efficiently deploying finite resources. 
Once a diagnosis of CRC is made, it is necessary to promptly stage the disease. This 
includes a full medical history and physical examination including digital rectal 
examination and rigid sigmoidoscopy for rectal cancer. Blood tests including 
complete blood count, liver and renal function tests, and carcinoembryonic antigen 
(CEA) are performed. Radiological imaging including a Computed Tomography (CT) 
scan of the chest, abdomen and pelvis, in addition to Magnetic Resonance Imaging 
(MRI) of the pelvis for rectal cancer. The management of CRC is guided by both 
patient and disease factors. It is recommended that all patients with CRC are 
discussed in a colorectal multidisciplinary meeting (MDM) (18). At that stage a 
decision is made regarding planning of treatment (Figure 1).  
 
Figure 1- Simplified current diagnosis and treatment pathway for non-metastatic 
(stage I-III) CRC in New Zealand. 
If the disease is non-metastatic (stage I-III), surgical resection is the standard of 
treatment in colon cancer. For those diagnosed with rectal cancer, there is a 
possibility of neoadjuvant treatment in the form of either radiotherapy alone or 
chemo-radiotherapy in order to downstage the disease prior to surgery. The 
decision to choose neoadjuvant therapy depends on many factors including both the 
extent of disease at diagnosis and the patients’ suitability to undergo treatment. 
Less advanced rectal cancer is less likely to require neoadjuvant treatment. 
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Similarly, adjuvant chemotherapy is given to selected patients following surgery 
that are thought to be at increased risk of recurrence due to more advanced TNM 
staging. Methods that assist in the earlier diagnosis of CRC may lower the numbers 
of patients requiring neoadjuvant and adjuvant treatment and help decrease the 
overall cost of treating this disease while also improving patient outcomes. 
1.1.2 Bowel Cancer Screening 
Population level bowel cancer screening programmes have been demonstrated to 
decrease mortality from CRC (19, 20). Additionally, screening programmes have 
also been found to identify CRC at an earlier stage, which leads to decreased costs 
as less intensive treatments are required (21). The New Zealand Ministry of Health 
is currently implementing the National Bowel Screening Programme (NBSP). This 
will be introduced to District Health Boards on a staged basis, and is planned to be 
in place nationally by 2021. Screening programmes have been shown to be either 
cost effective or cost saving wherever they have been implemented (22). Recent 
data on the Australian bowel-screening programme has predicted that CRC-related 
mortality and overall healthcare costs can both be decreased with any increase in 
the screening participation rate (23). While colonoscopy has been adopted as an 
effective first line screening tool in a number of countries, issues with resources and 
invasiveness, as discussed in the previous section, have precluded its universal 
adoption (24). An increasing number of countries, including New Zealand, have 
instead opted for stool-based screening methods (24).  
Stool-based population screening programmes have been adopted in at least twelve 
countries (24). Stool-based testing includes Faecal Occult Blood Testing (FOBT) and 
Faecal Immunochemical Testing (FIT). FOBT is a guaiac based test that detects 
occult blood in the stool, FIT are immunoassays specific for human haemoglobin 
(25). FIT is preferable over FOBT for population based screening due to its higher 
sensitivity (79% vs. 71.2%) and comparable specificity (94% vs 93.6%) for CRC 
detection (26-29). The major limitation of FIT as a screening tool is its limited 
sensitivity for detection of adenomas and early stage CRC. FIT has a higher rate of 
false-negative results for carcinoma in situ and T1 cancer when compared to more 
advanced CRC, with a test sensitivity as low as 66.7% for these early lesions (30). A 
diagnostic or screening test with improved sensitivity compared to FIT may 
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increase pick-up rates of early stage CRC and thus contribute to both decreased CRC-
related mortality and decreased overall healthcare expenditure. 
While the adoption of population based screening is a positive step toward reducing 
CRC-related mortality, screening uptake is not universal and in New Zealand will 
only be available between the ages of 60-74 (24). A considerable number of patients 
with CRC are either not eligible or do not participate in screening, likely only being 
diagnosed after becoming symptomatic following progression of disease (31). 
Uptake rates of stool-based screening have been reported at only 41-57% (17, 32, 
33) and research suggests that there is a patient preference for blood-based, 
compared to faecal-based, screening if it were available (34). From a recent NBSP 
pilot study, a participation rate of 56.9% was seen in a New Zealand population (35). 
A study from 2012 found that 78% of those surveyed would prefer to give a blood 
sample for CRC screening over a faecal-based test (34). These findings are 
compounded by recent data from Australia suggesting that if the screening 
participation rate were to rise from 40% to 60% there would be significant 
decreases in CRC-related mortality as well as significant healthcare cost savings 
(23). Were a blood-based screening test, or ‘liquid biopsy’, available it may serve to 
increase participation rates and thus take advantage of some of these potential 
benefits. 
1.2 Liquid Biopsies 
The concept of a liquid biopsy stems from the discovery that cancer cells secrete 
molecules into the circulation that contain signature markers of their cell of origin 
(36, 37). The advantages of blood-based screening include minimal invasiveness, 
repeatability, and possible improved uptake compared to stool based methods (34). 
If an effective liquid biopsy biomarker were established it might have a role in 
augmenting, or replacing, the current stool-based screening strategies. 
Currently, no liquid biopsy markers are routinely used for screening or diagnosis of 
CRC. CEA is commonly used to monitor for recurrence; however, issues with 
sensitivity and specificity negate its use in diagnosis or screening (38). The US Food 
and Drug Administration has recently approved a blood-based marker that 
measures methylated Septin9 DNA by real-time polymerase chain reaction (PCR) 
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for CRC screening. While early case-control studies of this test reported a 70% 
sensitivity and 90% specificity for CRC detection, testing in an asymptomatic cohort 
found only 35% sensitivity with 91% specificity for the detection of stage I CRC. This 
would hinder its viability for population-based screening for early stage cancers 
(39-41). Another blood-based marker in CRC is the neutrophil-to-lymphocyte ratio 
(NLR), increased NLR at diagnosis has been significantly associated with poorer 
tumour differentiation and overall survival and it may have a role as a prognostic 
marker (42, 43). For any potential liquid biopsy biomarker to replace current stool-
based screening methods, it would need to have at least comparable sensitivity and 
specificity to strategies already in use. 
The development of liquid biopsy biomarkers with higher sensitivity for early 
detection of CRC has the potential to improve rates of CRC-related mortality in 
addition to possible cost-saving benefits. Novel diagnostic and screening strategies 
may be used either in conjunction with, or as a replacement for, current stool-based 
screening programmes. Various molecules have been identified as having potential 
as liquid biopsy markers. These include circulating tumour cells that originate from 
primary or metastatic sites, circulating cell-free tumour DNA, as well as microRNA 
(miRNA) which can be free in the circulation or encapsulated in extracellular 
vesicles (EVs) (44, 45). 
A significant amount of ongoing research is focused on the rapidly developing field 
of EV biomarkers. EVs are stable in the circulation and under various storage 
conditions (46, 47). The contents of EVs are protected in the circulation by 
encapsulation within a membrane; in addition, EV contents reflect the unique 
profile of their cell of origin (46, 47). There has been increasing interest in 
examining the non-coding RNAs within these EVs, particularly miRNA, as 
candidates for liquid biopsy biomarkers. 
1.2.1 Extracellular Vesicles 
EVs are a diverse group of membrane bound particles released from all human cells 
(48). They have become of particular interest to cancer biomarker researchers due 
to the ability of tumour cells to secrete large amounts of EVs in comparison to 
normal cells, which also contain protected tumour-specific cargo (49-51). EVs also 
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have a role as functional mediators of cancer cell biology. They can act in a paracrine 
fashion locally within the tumour microenvironment, and in an endocrine manner 
at distal sites via the circulation (46, 52, 53).  
EVs are divided into 3 main classes based on biogenesis: exosomes (~40-100nm) 
originate in multivesicular bodies from the cell’s endosomal system; microvesicles 
(or ectosomes/microparticles; 100nm-1µm) are formed from outward budding of 
the plasma membrane (54-56); and, apoptotic bodies (1-5µm) arise from dying cells 
undergoing apoptosis (57-59). In addition to these classes, some cancer-specific 
subtypes of EVs have been identified. Oncosomes (100-400nm) are produced by 
non-transformed cells and their contents can produce oncogenic effects (60, 61), 
whereas large oncosomes (1-10µm) arise from malignant cells and are more 
atypical in morphology (62-64).  
 
Figure 2- Origin of Extracellular Vesicles (EVs) demonstrating the formation of EVs 
from the parent cell and the encapsulation of their contents, including miRNA, within 
a membrane in the circulation  (adapted from de Jong et al., 2019 (65)). 
EVs contain a range of contents including proteins, lipids, and RNA that directly 
reflect the parent cell of origin (Figure 2; 46, 47). EVs are robust within the 
circulation, thus their unique contents offer an attractive target as a possible liquid 
biopsy biomarker. It also appears that cancer EVs contain higher amounts of certain 
molecules such as miRNA compared to EVs from other cell types (66). Additionally, 
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within tumour cell EVs it has been observed that pre-miRNA can be processed to 
mature-miRNA, a feature that is not present in EVs from non-cancerous cells (66). 
This may further add to the differentiation and specificity of the unique constituents 
of tumour cell EVs that adds to their potential as biomarkers in CRC. 
1.2.2 Extracellular Vesicle miRNA 
miRNA are single stranded, non-coding RNA molecules of approximately 18-22 
nucleotides that have been implicated in a host of normal biochemical processes 
including cell differentiation, proliferation, and apoptosis (67-70). miRNA levels are 
significantly dysregulated in CRC tumour tissue compared to normal colonic 
mucosa (71). These abnormally expressed miRNAs may play a role in tumour 
suppression, tumorigenesis and progression (72, 73). As the profile of miRNA that 
is produced by tumour cells is significantly different to healthy cells they offer an 
attractive target as possible liquid biopsy biomarkers. 
In addition to dysregulation in tumour tissue, accumulating research points to the 
existence of unique miRNA signatures in body fluids that may function as diagnostic 
and prognostic biomarkers for cancer (74-76). Circulating miRNAs remain stable in 
serum or plasma under a host of unfavourable conditions including extreme 
temperatures and repeated freeze-thaw cycles (77, 78). The stability of miRNAs in 
the circulation is due to a number of factors protecting them from degradation by 
RNAses, this includes their encapsulation in EVs (Figure 2), in addition to their 
association with carrier molecules such as Argonaute-2 and lipoprotein complexes 
(78-80). This notable stability increases the appeal of these molecules as potential 
biomarkers in CRC and other diseases. 
There is some evidence that EV-specific miRNA may be of greater utility with regard 
to developing a liquid biopsy in CRC compared to total circulating miRNA levels.  
This is based on the theory that EV miRNA profiles are more specific for tumour-
derived signatures than total circulating miRNA due to the large volume of EVs 
released by tumour cells (81). While sources of circulating EVs include platelets, red 
blood cells, and immune cells, in addition to tumour cells (82), CRC tumour cells 
have been shown to release EVs in abundance in-vitro (83). This data suggests that 
EV miRNAs have significant potential as liquid biopsies due to both their robustness 
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in the circulation and subsequent storage in addition to the specificity of their 
contents in reflecting the genetic makeup of their cell of origin. 
1.3 EV-miRNA in colorectal cancer 
EV-miRNA are dysregulated in numerous cancers and have recently become the 
focus of an extensive amount of work aiming to identify novel biomarkers of disease 
(71, 81, 84). There have been a substantial number of circulating miRNAs suggested 
as potential CRC biomarkers; examples include miR-1246, miR-19a, miR-23a and 
miR-183 (85-87). Studies have focused mainly on EV-miRNA derived from primary 
CRC tissue culture, in-vitro CRC cell lines, serum or plasma. Focusing specifically on 
EV miRNA that become dysregulated in stage I and II CRC may have greater clinical 
relevance to developing a blood-based test for diagnostic or screening purposes. 
The earlier CRC can be detected the lower the overall mortality as well as overall 
healthcare expenditure.   
1.3.1 miR-1246 
miR-1246 has attracted interest as a possible biomarker in CRC. EV miR-1246 levels 
have been shown to be elevated in serum, plasma and CRC cell lines, but with 
conflicting results in tumour tissue (81, 85, 86, 88-91). miR-1246 may have a role in 
promoting tumour progression. Yamada et al. have demonstrated that miR-1246 
and transforming growth factor (TGF-β) are transported in microvesicles from CRC 
cells to endothelial cells. Their subsequent effect on Smad 1/5/6 signalling 
modulates the tumour environment to promote angiogenesis and tumour growth 
(90).  
miR-1246 in tissue and CRC cell culture 
miR-1246 has been observed to be both elevated and suppressed in CRC tumour 
compared to normal colonic tissue (90, 91). Scarpati and colleagues (2014) 
examined CRC tissue from 57 CRC patients, of which 24 were stage I and II, 
compared to normal stroma. Their results found miR-1246 to be upregulated 
relative to normal colonic tissue, with a 2.12 fold change (p<0.0001; 91). Yamada et 
al. (2014) conversely, demonstrated a mild decreased expression of miR-1246 in 
tumour tissue compared to normal colonic tissue in 33 CRC patients of which 13 
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were stage I and II (90). Methodology differed in the processing of tissue samples 
between these studies. Scarpati and colleagues (2014) liberated tissue samples 
from formalin-fixed, paraffin-embedded (FFPE) slides, whereas Yamada et al. 
(2014) immediately froze the CRC tissue in liquid nitrogen (90, 91). This may be a 
possible reason for conflicting findings.  
Yamada and colleagues also examined EVs isolated from CRC culture media from 
DLD-1, WiDr, SW480 and COLO201 cell lines (90). Their findings demonstrated a 
significant enrichment in expression of miR-1246 within the EVs when compared 
to intracellular levels (p<0.01; 90).  A further study also observed a similar pattern, 
miR-1246 was found to be elevated in CRC cell culture media EVs when isolated 
from the LM1863 cell line when compared to the cell lysate (88). The findings of 
these studies suggest that miR-1246 may be packaged into EVs and subsequently 
released from CRC cells. This finding offers promise that miR-1246 may be elevated 
in EVs in the bloodstream. 
miR-1246 in plasma and serum EVs 
EV miR-1246 has been observed to be elevated in stage I and II CRC in both serum 
and plasma in a number of studies (81, 85, 86, 90). Serum EV miR-1246 was found 
to be elevated 2.23 fold in a cohort of 209 patients, of which 107 were stage I and II, 
when compared to 28 healthy controls (85). Serum EV levels have also been 
observed to decrease following resection of CRC tumours (86). Additionally, 
significantly elevated serum EV levels have also been associated with liver 
metastases in patients with CRC compared to healthy controls (85). 
In a study by Ogata-Kawata et al. (2014) examining serum EV levels of miR-1246 to 
differentiate 88 CRC patients of all stages from healthy controls found a 95.5% true 
positive and 9% false negative rate. Using Receiver Operating Characteristic (ROC) 
curves, a corresponding Area Under the Curve (AUC) of 0.948 was demonstrated. A 
further small validation cohort in the same study demonstrated a 90% sensitivity 
for differentiating stage I CRC patients alone from healthy controls (86).  
In addition to dysregulation in serum, altered plasma EV miR-1246 levels have also 
been observed. Plasma EV miR-1246 was significantly elevated when comparing 46 
stage II CRC patients to 50 healthy controls (p<0.0001; 81). Additionally in murine 
14 
 
models transfected with human CRC, elevation of plasma EV miR-1246 was 
demonstrated in 61% of samples (90). Circulating EV miR-1246 has been 
demonstrated to be dysregulated in both serum and plasma. In addition it appears 
to have an ability to discriminate early stage CRC patients from healthy controls, its 
role as a possible liquid biopsy biomarker warrants further examination. 
1.3.2 miR-19a 
A growing body of research is establishing the functional role miR-19a has to play 
in the development of CRC. Functional markers that become more dysregulated 
along with progression of disease are another possible target for potential liquid 
biopsy biomarkers. miR-19a is part of the miR-17-92 cluster consisting of six miRNA 
genes, miR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a (92).  
Among the miRNAs within the miR-17-92 cluster, miR-19a is an important 
oncogenic miRNA (93). Elevated expression of miR-19a has been associated with 
activation of the Wnt/β-catenin pathway. This activation appears to have an effect 
on tumour proliferation, invasion, progression and angiogenesis that has been 
demonstrated in a number of studies (94-96).  However, a recent study by Chen et 
al. (2018) has contradicted these findings and suggested that overexpression of 
miR-19a inhibits CRC angiogenesis and thus progression by inhibiting KRAS (97). 
Whilst the exact role of miR-19a remains to be fully defined, it can be seen from the 
current data that altering its expression has an effect on CRC tumours. 
miR-19a in CRC cell culture and tissue 
miR-19a has been observed to be enriched in EVs isolated from CRC cell culture 
models. It appears to be upregulated in A33 positive EVs isolated from culture from 
the LM1863 CRC cell line (88). It has been found to be upregulated in tissue samples 
from CRC liver metastasis when compared to primary stage I and II CRC tumours 
(98). The current data on miR-19a in tissue appears to be limited and may merit 
further assessment. 
miR-19a in serum EVs 
Serum EV miR-19a is upregulated in both early and late stages of CRC (85, 99). It 
was able to discriminate 107 stage I and II CRC patients from 16 healthy controls 
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(p<0.001; 85). Elevated levels of serum EV miR-19a were associated with serosal 
invasion, lymphatic invasion, lymph node and liver metastasis, in addition to higher 
TNM stage and poorer overall survival (85). It has also been observed by Chen et al. 
(2013) to be significantly increased in serum of CRC patients resistant to FOLFOX 
chemotherapy when compared to patients with a good response (p=0.009; 99). 
The current evidence suggests that miR-19a is dysregulated in the serum EVs of 
early stage patients. It may have a role in tumour development, as well as the 
response to chemotherapy. miR-19a appears to play an important functional role in 
CRC and may be a promising candidate for a liquid biopsy biomarker.  
1.3.3 miR-23a 
miR-23a has been observed to be dysregulated in CRC tissue and cell culture, 
additionally altered expression has been seen in EVs in both cell culture media and 
from the circulation (36, 86, 100-102). There is an increasing body of data regarding 
its possible role as a biomarker and it appears to be a potential candidate for a liquid 
biopsy. miR-23a forms a cluster with miR-27a and miR-24-2 (103). It has been 
suggested that 23a may promote the migration and invasion of CRC cells and also 
appears to have a role in promoting resistance to chemotherapy agents such as 5-
FU in at least two studies (103-105). 
miR-23a in tissue and CRC cell culture 
miR-23a has been shown to be upregulated in CRC tissue samples from patients of 
all stages in a number of papers, with at least a 2 fold change in expression, when 
compared to matched normal colonic mucosa (100-102). These findings have been 
reflected in CRC cell lines (DLD-1, HCT116, SW620, WiDr and SW480) where miR-
23a has been found to be overexpressed compared to the normal colonic tissue cell 
lines CCD18Co, FHC and CCD-841 CoN (101, 102). Furthermore, its presence has 
been found in EVs isolated from LIM1863 CRC cell culture media (88). 
Interestingly, it appears that miR-23a may be preferentially upregulated in earlier 
stage CRC tumour tissue. miR-23a had increased expression in CRC tissue from 
stage I and II patients when compared to both adenomas and carcinoma in 
situ (p=0.0001). Elevated miR-23a expression was specific to early stage CRC tissue, 
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as tissue from stage III and IV patients had lower miR-23a levels (p=0.0001; 103). 
While a biomarker which is elevated in early stage disease is promising, if it were to 
decrease again in late stage disease this may affect its utility as a liquid biopsy for 
screening as patients presenting with more advanced cancers may be missed. 
miR-23a in serum and plasma 
miR-23a has also been found to be elevated in EVs in CRC from the circulation (36, 
85, 86, 88). Plasma and serum EV levels have been shown to be upregulated in stage 
I and II CRC and to decrease post resection (36, 86). In addition, serum EV miR-23a 
appears to have potential in differentiating CRC from healthy controls with an AUC 
of 0.953, when comparing 88 CRC patients of all stage, of which 40 were stage I and 
II, against 11 healthy controls (86). miR-23a was found to be elevated 2.7 fold by 
Matsumara et al. (2015) when comparing serum EV-miRNA from a group of 209 
CRC patients, of which 107 were stage I and II, against 28 controls (85). 
A number of studies have demonstrated miR-23a may be dysregulated in early stage 
CRC. Furthermore, the literature has suggested it may have an ability to differentiate 
early stage CRC patients from healthy controls; this makes it an attractive target 
possible for a liquid biopsy. Although, a caveat of its use include the possibility of it 
decreasing in later stage disease.  
1.3.4 miR-183 
miR-183 has been demonstrated to promote proliferation and invasion of CRC in in-
vitro models (106). It has also been found to be overexpressed in CRC types with 
mismatch repair (MMR) deficiency (107). With regard to clinical outcomes, it has a 
correlation with elevated TNM stage, lymph node and distant metastasis, in addition 
to an association with decreased disease free survival and overall survival (108, 
109). It appears to be consistently dysregulated in tissue, but a role as a possible 
circulating EV biomarker does not appear to have been thoroughly investigated. 
miR-183 in tissue and CRC cell lines 
A study by Nagy et al. (2017) found miR-183 to be overexpressed in both colonic 
adenoma and CRC compared to normal colonic tissue (110). Other studies have 
demonstrated a significant elevation in CRC tissue compared to normal mucosa in 
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studies examining 94, 42 and 48 patients of all stages respectively (108, 109, 111). 
Its presence in EVs from CRC cell culture does not appear to have been established. 
miR-183 in the circulation 
miR-183 levels have been found to be significantly elevated in total plasma of CRC 
patients when compared to controls. It has been shown to decrease following 
resection and is associated with tumour recurrence (87). miR-183 appears to be 
consistently dysregulated in CRC tissue and its total levels in the circulation also 
appear to be elevated in the context of CRC. However, levels of expression in EVs in 
CRC does not appear to have been examined thoroughly. It is possible that miR-183 
may have potential as a novel EV miRNA biomarker.  
1.3.5 miR Panels 
An obstacle in finding a single EV miRNA that can function as a liquid biopsy 
biomarker is that all of the EV miRNAs discussed have been implicated in multiple 
pathologies, both malignant and benign. Increased levels of circulating miR-1246 
have been found in other cancers including oesophageal squamous cell carcinoma, 
metastatic cervical cancer and multiple myeloma (112-115). Dysregulation of miR-
19a is observed in oesophageal, bladder and gastric cancers, in addition to asthma 
and rheumatoid arthritis (116-120). The miR-23a~27a~24 cluster has been 
associated with acute leukaemia, bladder, hepatocellular, gastric, and pancreatic 
cancers (121-125). Furthermore, miR-183 has been implicated in a host of diseases 
including Acute Myeloid Leukaemia, Parkinson’s disease as well as a number of 
malignancies (126-128). From this data, it appears that many miRNA are involved 
in a host of different diseases. Another consideration is that, by its nature, CRC 
tumorigenesis is not an organised process. There may be significant diversity of EV 
miRNA profiles produced by different CRC tumours. Therefore, it is possible that 
finding a single EV miRNA marker that is both sensitive and specific for CRC will 
prove difficult. Combining a number of markers in a panel of EV miRNAs have been 
employed to attempt to mitigate against these factors.  
A number of studies that have examined a panel of miRNA together. This is to 
establish if their capacity to act as a liquid biopsy is superior when combined to any 
single miRNA alone. Yuan et al. (2016) developed a six EV miRNA panel that 
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compared 100 CRC patients (25 for each stage I-IV) as well as 50 controls. Their 
panel was able to differentiate CRC from healthy controls with an AUC of 0.68 and 
0.77 for stages I and II, respectively. This was superior to any lone EV miRNA (129). 
Similarly, Ogata-Kawata and colleagues (2014) studied seven EV miRNA panel, all 
were elevated in serum EVs from 88 CRC patients, of which 20 each were stage I and 
stage II, compared to 11 controls (86). Combined use of this panel did not show 
more diagnostic power than two miRNA alone, miR-1246 and miR-23a, which had 
AUC values of 0.948 and 0.953 for all stages of CRC respectively (86). While the 
concept of an miRNA panel is promising, data from the above studies is not 
definitive. Further examination of a different combination of EV miRNA markers 




The global burden of CRC is set to increase significantly over the next decade. 
Although New Zealand has one of the highest prevalence of CRC in the world, it 
appears to underperform internationally when it comes to diagnosing CRC at an 
early stage. The earlier a diagnosis of CRC is made, the better the patient outcomes 
and lower overall cost of treatment. Screening improves pick-up rates of earlier 
cancers with a corresponding decrease in the rates of more advanced cancers. 
However, current stool based screening methods are not without issue, including 
limited sensitivity in early stage disease, in addition to sub-optimal participation 
rates. A blood-based screening test in the form of a liquid biopsy is an attractive 
proposition that may help address these concerns. 
EVs are robust in the circulation and are produced in abundance by CRC cells. The 
contents of EVs directly reflect their cell of origin and examining these contents, 
such as miRNA, may provide a good target for a liquid biopsy. Identifying EV-miRNA 
within the circulation that are both sensitive and specific for CRC could help develop 
a blood-based screening test in the form of a liquid biopsy. This may contribute to 
earlier diagnosis of CRC, which could significantly help with decreasing both the 




1.5 Aims and Hypothesis 
1.5.1 Aims 
The overall aim of this study is to establish whether the microRNA miR-1246, miR-
19a, miR-23a and miR-183 can be used to differentiate early stage CRC from 
controls in both tissue and plasma EVs. This study will be performed in a well-
defined cohort of stage I and II CRC patients with matched CRC tumour tissue and 
normal colonic mucosa from the same patient. Plasma samples will include all 
patients in which tissue is examined in addition to further stage I and II patients for 
whom only plasma is available. Control plasma EVs will be sourced from a matched 
cohort of patients who have had an entirely normal colonoscopy to rule out any 
polyps or other colonic abnormalities that may affect expression of the candidate 
miRNAs. If these microRNAs are differentially expressed in tissue and circulating 
EVs then they may have utility as liquid biopsy biomarkers. 
The specific aims are: 
1. To determine whether there is differential expression of miR-19a, miR-23a, miR-
183 and miR-1246 in tumour tissue from stage I and II CRC patients compared to 
matched normal colonic mucosa from the same patients. 
2. To determine if there is differential expression of miR-19a, miR-23a, miR-183 and 
miR-1246 in plasma EVs from the above stage I and II patients in addition to further 
patients from whom only plasma is available, when compared to plasma EVs from 
healthy controls who have had an entirely normal colonoscopy. 
1.5.2 Hypothesis 
We hypothesise that the microRNAs miR-19a, miR-23a, miR-183 and miR-1246 will 
be differentially expressed in tumour tissue in stage I and II CRC patients when 
compared to matched normal colonic mucosa from the same patients. That miR-19a, 
miR-23a and miR-183 will demonstrate increased expression in tissue as shown in 
previous research, and miR-1246, which has been shown to be both over and 
underexpressed in tissue, will demonstrate dysregulation in either direction. 
Subsequently, changes in CRC tissue will lead to altered expression in plasma EVs 
released from CRC cells into the circulation when compared to plasma EVs from 
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healthy controls. Furthermore, we expect that this difference between the miRNA 
expression in the EVs of stage I and II CRC patients will differentiate CRC patients 













Chapter 2: Methods 
2.1 Patient Recruitment 
Patients were recruited for donation of blood and tissue for the Surgical Cancer 
Research Group (SCRG) CRC Biobank under ethical approval by Health and 
Disability Ethics Committee (‘Establishment of human tissue bank of surgical 
cancers for future unspecified research, ref: 15/CEN/143). MicroRNA measurement 
for the proposed study was approved by the Health and Disability Ethics Committee 
(‘Molecular biomarkers in colorectal cancer’, ref: 18/CEN/138). Consultation was 
also undertaken with the Ngāi Tahu Research Consultation Committee for this 
project. All work was performed in accordance with the Declaration of Helsinki and 
all patients provided written informed consent at the time of recruitment.  
The CRC biobank was created in October 2016, patients continue to be recruited on 
an ongoing basis. Data collected up to June 2019 was used. Patient demographic 
data was collected including; age, gender, ethnicity, presenting symptoms as well as 
co-morbidities and medications.  Information relating to their diagnosis and 
treatment of CRC was also collected. This included colonoscopy results, biopsy 
findings, imaging, surgical operation notes and pathology reports. Study data was 
collected and stored using REDCap data capture system hosted by Otago University 
in a secure database (130).  
Inclusion criteria for the CRC group were patients over the age of 18 who were being 
treated for CRC at Wellington Hospital. Patients were diagnosed on endoscopy at 
Wellington Hospital, or were referred to Wellington Hospital following diagnosis in 
Hutt Valley or Wairarapa Hospitals.  
Exclusion criteria were patients who had their surgery performed in a private 
hospital, those who were under the age of 18, emergency presentations and patients 
who had significant cognitive impairment that precluded them from providing 
informed consent.  
Recruitment of patients and collection of samples was carried out by a team of 
researchers at the University of Otago, Wellington. Recruitment involved 
identification of patients, consent, data entry, database audit, blood collection, and 
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assistance with collecting tissue at time of surgery. Suitable patients were found 
through MDMs, outpatient clinics and elective theatre lists. The author was 
responsible for patient identification, recruitment, blood sample collection and 
processing between January and December 2019. 
2.1.1 Patient Selection 
From the Colorectal Biobank, patients with stage I and stage II CRC were identified 
for the study, usually from outpatient clinics. Patient enrollment was at the time of 
diagnosis of CRC, prior to any treatment. Stage I and II patients with matched tissue 
and normal mucosa were included. Tissue from patients who had received 
neoadjuvant radiotherapy was not included as this has been shown to effect miRNA 
expression levels in CRC tissue (131). 
All stage I and II CRC patients that had plasma samples available were also 
identified, this included all the above patients who provided tissue samples. In a 
number of cases there was no tissue available but plasma alone had been collected. 
Staging status was based on post-operative staging as recorded at the Wellington 
Hospital Colorectal MDM. All plasma samples were collected at the initial clinic 
appointment following diagnosis and preoperative staging was also recorded. If any 
change in staging occurred following neoadjuvant treatment, these patients were 
excluded from the plasma analysis, as they may have had more advanced disease at 
the time of plasma collection. 
Control patients were selected from those who were referred to endoscopy with a 
suspicion of CRC but were found to have an entirely normal colon following a full 
colonoscopy. They were age and sex matched to the CRC patients. Consent was 
obtained prior to colonoscopy. All control patients that were recruited were 
symptomatic in the form of abdominal pain, weight loss, change in bowel habit or 
perirectal bleeding. Control patients were required to have a complete colonoscopy 
to the caecum without any evidence of CRC, adenomatous polyps or inflammatory 
conditions of the colon such as Ulcerative Colitis, Crohn’s Disease or infective colitis. 
This was to ensure there was no other colonic pathology occurring which may have 




2.2 Sample Collection 
Venous blood samples were taken from patients at the time of recruitment. This was 
always prior to any neoadjuvant treatment or surgery. Blood samples were 
collected using a 21G BD™ vacutainer blood collection set into sodium citrate 
collection tubes (3.2% 0.109 M) then centrifuged within 30 minutes of withdrawal 
at 3000 x g for ten minutes to separate the plasma. Plasma samples were separated 
into aliquots and stored in a -80°C freezer. EDTA and SST II Gel tubes were also used 
to collect venous samples that were used to perform biochemical and 
haematological tests in the hospital laboratory. This included Full Blood Count 
(FBC), CEA and C Reactive Protein (CRP). Blood sample tubes from which plasma 
EVs were isolated were taken following the samples that were sent to the hospital 
laboratory. This was in order to avoid cellular and skin debris from the initial 
venipuncture contaminating plasma EV preparations. 
Tissue samples were collected immediately following surgical resection of the 
specimen in the operating theatre. Once the specimen was resected a samples of 
central tumour tissue as well as a section of normal colonic mucosa. These samples 
were then immediately stored in RNAlater Stabilization Solution™ (ThermoFisher 
Scientific) according to manufacturer’s protocol.  
2.2.1 Tissue RNA extraction 
Tissue samples of tumour tissue and normal colonic mucosa were weighed to 
quantify their mass in milligrams (mg), the manufacturers recommendations were 
for 30-100µg of tissue, depending on the yield and purity of RNA being obtained. 
Samples were then homogenized in QIAzol Lysis Reagent™ solution using a mortar 
and pestle until all visible tissue particles had dissolved. RNA was then extracted 
using the miRNeasy Mini™ kit with the supplied miRNeasy Mini™ spin columns (all 
Qiagen) using a phenol-chloroform based extraction method according to the 
manufacturer’s instructions. The final RNA product was eluted in 30 µL of nuclease 
free water and stored at -80°C. The concentration and quality of RNA was assessed 
using a NanoDrop™ 2000 Fluorospectrometer (ThermoFisher Scientific). The 
concentration of RNA in ng/µL was recorded for tumour tissue and normal colonic 
mucosa. In addition to concentration, quality of the RNA extracted was assessed by 
26 
 
recording the 260/280 values. This is a ratio of absorbance at 260 nm and 280 nm 
on a fluorospectrometer, with a value of 2.0 considered of ideal purity of RNA, and 
values between 1.8 and 2.2 deemed of acceptable quality (132).  
2.2.2 Plasma Extracellular Vesicle isolation and RNA extraction 
Plasma extracellular vesicles were isolated using size exclusion chromatography 
(SEC) columns. qEVoriginal 70™ columns were used in conjunction with an 
automated collector; the Izon Automated Fraction Collector™ (both Izon Science). 
Five-hundred microlitres of plasma was added to the column and fractions seven, 
eight, nine and ten were collected using the automated fraction collector according 
to the manufacturer’s instructions. EVs within the collected fractions were 
subsequently pooled and added to a thin walled 17 mL ultracentrifuge tube 
(ThermoFisher Scientific). The remaining volume of the tube was filled with 12 mL 
1 x Phosphate Buffered Saline (1 X PBS). These tubes were then placed in a swing 
bucket rotor ultracentrifuge (ThermoFisher Scientific) at 4˚C, at 100,000 x g for two 
hours to form an EV pellet. 
The EV pellet was re-suspended in 300 µL 1X PBS. RNA isolation was subsequently 
performed using the Total Exosome RNA and Protein Isolation Kit (Invitrogen) 
according to the manufacturer’s instructions. The final RNA product was eluted in 
50 µL of nuclease free water and stored at -80°C. 
2.2.3 Reverse Transcription 
For both tissue RNA and plasma-EV RNA, reverse transcription (RT) was performed 
using the TaqMan® Advanced miRNA cDNA Synthesis Kit (ThermoFisher 
Scientific). For each tissue sample, 5 ng of RNA was used. For plasma EV samples       
2 µL of RNA was used. For both, the protocol was followed as per the manufacturer’s 
instructions. Briefly, an initial polyadenylation step was performed at 37°C for 45 
minutes, followed by heat inactivation at 65°C for 10 minutes. This was followed by 
an adaptor ligation reaction at 16°C for 60 minutes. RT was then performed with 
incubation at 42°C for 15 minutes, with subsequent heat inactivation at 85°C for 5 
minutes. The cDNA product was stored at -20°C until use. Pre-amplification was 
performed according to the manufacturer’s instructions using an initial denaturing 
step at 95°C for 3 seconds followed by an anneal/extend phase at 60°C for 30 
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seconds, this cycle was repeated 14 times. The amplification product was also 
stored at -20°C. 
2.2.4 Quantitative PCR 
Pre-amplified cDNA samples from the above reaction were diluted 1:10 with 
nuclease-free water. Quantitative Reverse Transcription PCR (RT-qPCR) was then 
performed with the TaqMan® Fast Advanced Master Mix (ThermoFisher Scientific) 
on a Corbett RotorGene 6000 with TaqMan® advanced miRNA Assays 
(ThermoFisher Scientific). Specific assays for hsa-miR-19a-5p, hsa-miR-23a-3p, 
hsa-miR-183-3p, hsa-miR-1246-5p, hsa-miR-16-3p and hsa-miR-345-5p were used. 
Both hsa-miR-16-3p and hsa-miR-345-5p were employed as endogenous reference 
genes based on previously published research that has examined both CRC tissue 
and plasma EVs (85, 133-135). The total reaction volume of each sample was 10 µL, 
which included 2.5 µL of diluted cDNA. Negative reactions containing RNAse free 
water instead of cDNA were included in every experiment.  
All reactions were performed in duplicate and cycle threshold (CT) values within 0.5 
were considered acceptable. The following cycling conditions were utilized: 95°C 
for ten minutes, followed by 40 cycles of 95°C for ten seconds, and 60 °C for one 
minute. Expression levels of miRNA were quantified using the Rotor-Gene software 
version 1.7.75. A threshold of 0.07657 was set across all tissue and EV experiments. 
A CT cut-off value of 35 was used. For miRNA samples where this cutoff threshold 
was exceeded, a CT value of 35 was assigned as the miRNA expression levels were 
too low to be adequately quantified when using our methods. 
Endogenous controls in the form of reference genes were employed for all tissue 
and plasma EV samples. For tissue, miR-16 and miR-345 were used. The mean 
expression of both of these genes was calculated as the geometric mean. In plasma 
EVs, miR-16 alone was used as miR-345 did not demonstrate consistent expression 
across patient groups (supplementary Figure S1). miR-16 has previously been used 
as an endogenous reference gene in published studies examining both CRC tissue 
and plasma EVs in CRC (85, 133, 134). miR-345 has also been used as an endogenous 
control in the published literature and recommended as a stable endogenous 
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reference  gene in CRC in a number of studies examining both CRC tissue and 
circulating EVs (133, 135).  
2.3 Data Analysis 
2.3.1 Calculating relative miRNA expression (ΔCT) 
Expression levels of candidate miRNA are expressed as ΔCT, or the change in CT 
value relative to endogenous reference genes. In tissue, the relative expression 
values of target miRNAs (miR-19a, miR-23a, miR-183, and miR-1246) were 
calculated using the 2-ΔΔCt method (136). To calculate CT for each sample, the 
geometric mean values of the endogenous reference genes (miR-16-3p and miR-
345-5p) was subtracted from the CT value of the miRNA of interest. The CT value 
for normal mucosa was subsequently subtracted from the paired CT value for 
tumour tissue from the same matched patient (CT), and log transformed to 
calculate the relative expression (2-CT). For all candidate miRNA samples where 
the cutoff threshold of 35 was exceeded, a value of 35 was assigned, as the miRNA 
expression levels were too low to be detected by our current RT-qPCR set up. 
With respect to plasma-EV miRNA, CT was calculated by subtracting the CT value 
of the endogenous reference gene (miR-16-3p) from the CT value of the miRNA 
being assessed for each CRC or control sample. The relative change in expression, 
CT, was calculated by subtracting the mean CT value of the control group from 
the mean CT values from the CRC group for each of the candidate miRNA. Similarly 
to tissue, the mean fold change in expression was then log transformed as 2-ΔΔCt . 
The relative changes in mean miRNA expression between tumour tissue and plasma 
EVs were examined. This was calculated by subtracting the ΔCT for tumour tissue 
from that of EVs for the same sample and calculating the change in expression using 
the same 2-ΔΔCt method. 
2.3.2 Correlation of patient variables 
At the time of patient recruitment, a number of patient variables were recorded. 
These include patient demographics such as age, gender and ethnicity, in addition 
to blood-based variables including CEA, CRP and Neutrophil to Lymphocyte ratio 
(NLR). Finally, following surgery, tissue-based pathological variables were recorded 
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including perineural invasion (PNI) extramural venous invasion (EMVI), 
lymphovascular invasion (LVI) and mismatch repair proficiency/deficiency 
(pMMR/dMMR) from patient notes following pathological examination of the 
surgical specimen. Correlation between these variables and miRNA using Pearson’s 
and Spearman’s rank correlations, for parametric and non-parametric data 
respectively, were evaluated. This was to assess if the expression of each variable 
was independent, or possibly related to, miRNA expression.  
In the tissue analysis, a subset of patients existed with elevated expression of two of 
the candidate miRNA when compared against the rest of the tumour tissue group. 
In order to examine this further, these groups were subdivided into ‘high 
expression’, taken as a greater than two-fold increase, and ‘normal expression’ 
subgroups. These groups were then examined to establish if there were any 
significant difference in clinical or pathological variables.  
2.3.3 ROC Curve Analysis 
In order to assess the capacity of a variable, such as miRNA expression, to 
discriminate between CRC and controls, ROC curve analyses were employed. The 
values of a variable for CRC cases against controls were plotted into a ROC curve, 
subsequently the AUC was calculated. There were a number of instances where two 
variables were added together to create a combined ROC curve analysis, this was 
performed using methods described by Pepe et al. (2000; 137). This was to assess 
if two variables, when combined, were additive in their ability to differentiate 
control cases from CRC. Firstly, assessment for any correlation, as described above, 
was performed to ensure that expression of either variable was independent of one 
another. Subsequently, all the values for CRC cases and controls were listed 
together. From this list, any significant outlying data points were excluded using the 
ROUT method (138).  
The remaining figures were then reviewed to ensure normal distribution, the 
largest value was identified and assigned an arbitrary value of 1. Subsequently all 
the remaining values were divided by this largest value to give the fraction relative 
to the highest chosen value. Any outliers that were greater than the chosen greatest 
figure were also given a value of 1, consequently for each variable every patient had 
a value between 0 and 1. This corresponded to their relative expression of the 
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variable relative to the largest value. Fractions for multiple variables were added 
together for every patient. Thus, when two variables were combined for each 
patient, a maximum value of two could be achieved. These combined values for CRC 
against controls were then used in a ROC curve analysis to assess their ability to 
discriminate between groups. 
2.3.4 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 8.0.2 
software. Results were expressed as mean ± standard deviation. For comparisons of 
numerical data, either paired or unpaired t tests, in addition to one-way ANOVA 
with Tukey post hoc analysis were used. For non-numerical data, chi-squared tests 
were employed. Values of p<0.05 were considered statistically significant. 
With regard to the tissue analysis paired t tests were performed to compare the CT 
of target miRNAs between CRC tumour tissue and normal colonic mucosa from the 
same patient. For the plasma EV analysis, unpaired t tests were performed to 
compare CT values of the target miRNA between the CRC patients and the control 
group. For all figures in which ΔCT is examined (Figures 5, 7 and 8) the y-axis has 
been reversed. This was implemented as a ΔCT values are in reverse log order, thus 
reversing the axis converts data points to reflect the actual directional change in 
expression. 
For correlations between expression of miRNA and other variables, one variable 
was plotted on each of the x and y-axes. When correlating with CT the log2 of the 
variable was used. Subsequently, a Spearman’s or Pearson’s correlation was 
computed (r), then a two-tailed t-test with a 95% confidence interval was 















Chapter 3: Results 
3.1 Patient Demographics 
From October 2016 to August 2019, 321 patients were recruited to the SCRG, CRC 
biobank from Wellington Hospital. Of the total biobank patients, the average patient 
age was 67.55 years (range 27-88 years). The majority of patients are of New 
Zealand European ethnicity (83.8%), followed by Māori ethnicity (6.9%).  
Sixty-three patients in the biobank are healthy controls without CRC. Of these, 30 
patients had an entirely normal colonoscopy without any evidence of CRC, polyps 
or other bowel abnormalities. These patients were included as the healthy control 
patients in this study.  Of the remaining 259 patients, 80 have stage I or II CRC 
(30.8%). Fourteen patients were excluded from analysis as they had down staging 
of their disease following neoadjuvant treatment; this left 66 stage I or II patients 
with plasma. Forty-two of these patients with plasma also had matched CRC tumour 
tissue and normal mucosa that was included for tissue analysis. 
 
Figure 3 - Selection of patients from CRC biobank. 
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3.1.1 Patient cohort with available tissue samples 
There was a total of 42 patients with matched tumour tissue and normal colonic 
mucosa. The mean age of this group was 68.5 (±12.56) years, 19 of the 42 (45.2%) 
were female (Table 2). The majority (83.3%) were of NZ European ethnicity. Nine 
patients (21.4%) were stage I, with the remaining 33 (78.6%) being stage II. The 
majority (88.1%) of CRC originated in the colon, of which 25 were ‘right-sided’ with 
regard to the relation to the splenic flexure. 
Total 42 
Mean Age (±SD) 68.5 (12.56) 
Female (%) 19 (45.2) 
Male (%) 23 (54.8) 
Ethnicity (%)  
NZ European 35 (83.3) 
Māori 2 (4.7) 
Other 5 (12.0) 
TNM Stage (%)  
Stage I 9 (21.4) 
- T1 - 3 (7.1) 
- T2 - 6 (14.2) 
Stage II 33 (78.6) 
- T3 - 27 (64.3) 
- T4a - 5 (11.9) 
- T4b - 1 (2.4) 
Colon 37 (88.1) 
- Right sided - 25 (59.5) 
- Left sided - 12 (28.6) 
Rectum 5 (11.9) 
Table 2- Patient demographics and tumour characteristics for tissue samples.  
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3.1.2 Patient cohort with available plasma samples 
Patients included in the plasma group compromised all 42 patients with tissue, in 
addition to 24 patients from which only plasma was available (Table 3).  
 CRC Controls p value 
Total 66 30  
Mean Age (±SD) 67.5 (11.5) 63.79 (11.1) 0.1486 
Female (%) 33 (50) 18 (60) 0.3628 
Male (%) 33 (50) 12 (40)  
Ethnicity (%)    
NZ European 57 (86.3) 22 (73.3) 0.2976 
Māori 2 (3.0) 2 (6.7)  
Other 7 (10.6) 6 (20.0)  
TNM Stage (%)    
Stage I 20 (30.3)   
T1 7 (10.6)   
T2 13 (19.7)   
Stage II 46 (69.7)   
T3 38 (57.6)   
T4a 7 (10.6)   
T4b 1 (1.4)   
Site (%)    
Colon  52 (78.8)   
Right sided 34 (51.5)   
Left sided 18 (27.3)   
Rectum 14 (21.2)   
Neoadjuvant 
treatment 
7 (10.6)   
No Neoadjuvant 
treatment 
7 (10.6)   
 
Table 3 - CRC patient and control demographics and tumour characteristics for 





For patients included in the plasma analysis, the mean age at diagnosis for CRC 
patients was 67.5 (±11.5) years. The mean age of the control patients was 63.8 
(±11.1) years (Table 3). There was no significant difference in age between the 
control and CRC groups on an unpaired t-test (p=0.1486). Nor was there any 
significant differences in gender or ethnicity between the groups when a chi-
squared test was performed.  
The majority of patients were of NZ European ethnicity, which composed 73.3% and 
86.3% for control and CRC groups respectively. The majority of CRC patients were 
stage II (69.7%). Most of the CRC tumours included in the study originated in the 
colon (66.25%).  There is a higher proportion of rectal cancers in the plasma 
analysis (21.2%), when compared to tissue (11.9%). This is due to the exclusion of 
patients who received neoadjuvant therapy from tissue analysis. Of the rectal cancer 
patients, half received neoadjuvant treatment.  
3.2 Quality control of extraction of RNA from tissue samples 
To determine whether the miRNA of interest were dysregulated in tumour tissue 
compared to normal mucosa, total RNA was extracted from matched tissue pairs 
and miRNA expression was quantified by RT-qPCR. 
Of the 42 matched pairs of tumour tissue and normal mucosa, RNA extraction was 
previously performed for 18 patients, values for the weight of these samples was 
not available. The author processed the remaining 24 patient samples.  
Mean values of 36.09 (±16.89) mg and 33.64 (±19.87) mg for weight were 
comparable between tumour tissue and normal mucosa respectively. For RNA, 
mean concentration values of 702.5 (±663) ng/µL and 1070 (±1059) ng/µL for 
normal mucosa and tumour tissue respectively were also broadly similar. Quality of 
the RNA extracted was assessed by recording the 260/280 values, the average of 
which were 2.061 (±0.043) and 2.051 (±0.031) for tumour tissue and normal 
mucosa respectively. Individual values for weight of tissue processed and 
concentration of extracted RNA are included in supplementary Tables S2 and S3.  
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3.3 Quality Control of RT-qPCR 
Endogenous reference genes were used for the tissue and plasma EV analyses. 
Relative expression values of the candidate miRNA is expressed as ΔCT, which is the 
change in CT value relative to the endogenous reference genes. Both endogenous 
reference genes have been used as controls in previous research when examining 
CRC tissue and plasma EVs (85, 133-135).  To be effective endogenous controls 
there should be no significant difference in their expression between comparator 
groups. For tissue, both miR-16 and miR-345 were used. Mean values for each 
endogenous reference gene, in addition to their mean combined values, as the 
geometric mean, demonstrated no significant differences on a paired t-test (Table 4 
and Figure 4 A-C). 
 
Normal Mucosa (±SD) Tumour Tissue (±SD) 
miR-16 17.09 (1.98) 17.46 (2.00) 
miR-345 24.55 (2.01 24.48 (1.87) 
Geometric Mean  20.85 (1.96) 20.97 (1.83) 
Table 4 - mean CT values for endogenous reference genes in tissue samples 
In plasma EVs, miR-16 alone was used as miR-345 did not demonstrate consistent 
reliable expression. The mean CT values for plasma EV miR-16 were 24.71 (±4.13) 
and 23.73 (±3.02) for controls and CRC patients respectively. miR-345 was only 
expressed in 14 of 19 (73.6%) control samples and 28 of 42 (66.7%) CRC samples. 
Mean CT values were 28.17 (±1.99) and 29.19 (±1.92) for CRC and control groups 
respectively, these relatively high CT values (cut-off CT = 35) are in keeping with low 
levels of expression of miR-345 in plasma EVs. This would affect its suitability as an 
endogenous reference gene. Of the samples that did express miR-345, there was no 
significant difference between the groups on an unpaired t-test, (p=0.1194, 




There were no statistically significant differences in expression of the endogenous 
reference genes when comparing CT values of CRC against controls in either tissue 
samples or plasma EVs (Figure 4). Therefore, they were suitable as endogenous 
reference genes to calculate the relative change in expression (ΔCT) of the candidate 
miRNAs: miR-19a, miR-23a, miR-1246 and miR-183. 
 
Figure 4 - Analysis of endogenous reference genes. (A) Raw CT values for miR-16 
comparing normal mucosa and tumour tissue (p=0.1546, paired t-test). (B) Raw CT 
values for miR-345 comparing normal mucosa and tumour tissue (p=0.7903, paired t-
test). (C) Geometric mean (miR-16 & miR-345) comparing normal mucosa and tumour 
tissue (p=0.5857, paired t-test). (D) Raw CT values for miR-16 comparing plasma EVs 




3.4 MicroRNA expression in normal mucosa vs tumour tissue 
From the RNA extracted from both tumour tissue and normal colonic mucosa, 
relative expression levels (ΔCT) of the candidate miRNAs miR-19a, miR-183,          
miR-23a and miR-1246 relative to the geometric mean of the two reference genes       
(miR-16 and miR-345) was calculated (Figure 5).  
 
Figure 5 – miRNA expression in normal mucosa vs tumour tissue (A) miR-19a                     
(B) miR-23a (C) miR-183 (D) miR-1246. *** = p<0.001, paired t-test; note: reversed y-
axes. 
Statistically significant increases in tumour tissue miRNA expression were observed 
in two of the four miRNA. miR-183 was significantly increased in tumour when 
compared to matched normal mucosa (Figure 5 C), however it was only reliably 
expressed in 35 of the 42 samples, it had relatively low overall expression in tissue 
(mean CT 29.52 and 32.51 for tumour and normal mucosa respectively). miR-1246 
(Figure 5 D) also demonstrated a significant increase in expression in tumour tissue  
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and was expressed in 40 of the samples, this also exhibited low overall tissue 
expression (mean CT 29.82 and 32.16 for tumour and normal mucosa respectively). 
For both miR-183 and miR-1246, samples that demonstrated CT difference >0.5 on 
duplicate samples following three attempts at RT-qPCR were excluded from 
analysis. Using the 2-ΔΔCT method, the mean fold in expression was 210.6 (±575.1) 
and 147.9 (±494.6) fold increases in expression for miR-183 and miR-1246 
respectively. 
There was a trend towards an increase in expression in tumour tissue for miR-19a 
(Figure 5 A), however this was not statistically significant (p=0.0579). Following 
exclusion of a single prominent outlier from each of the tumour and normal mucosa 
groups, this p value increased to 0.2027.  
There were no significant relationships between tissue expression of the candidate 
miRNA and various clinical variables including age, gender or stage of CRC 
(Supplementary Table S4). Additionally, there was no association between left 
(including rectal) or right sided tumours, nor was there a relationship with 
commonly used tissue-based pathological variables in CRC such as PNI, LVI, MVI and 
MMR deficiency (Supplementary Table S4).  
For both miRNA that demonstrated overexpression in tumour tissue, the cohort was 
divided into ‘high expression’ and ‘normal expression’ subgroups (Supplementary 
Table S5 and S6). The high expression group was determined by a two-fold or 
greater change in expression in tumour tissue compared to normal mucosa. Females 
were significantly more likely to have high expression of both miR-183 and miR-
1246 on a chi-squared test (p=0.0354 and p=0.007 respectively; Supplementary 
Table S5). Additionally, there was a significant association between high miR-1246 
expression and NLR on an unpaired t-test (p=0.044; Supplementary Table S6). 
There were no other significant differences between high and normal expression 




3.4.1 ROC Curves and tumour tissue miRNA expression 
There was no evidence of correlation between the two differentially expressed 
miRNA in tumour tissue, which suggests these miRNA are expressed independently 
of each other (Figure 6 A). ROC curve analyses were subsequently compiled. 
 
Figure 6 – Discrimination of tumour tissue and normal mucosa by miR-1246 and miR-
183 expression (A) Correlation of miR-183 and miR-1246 CT values (Spearman’s 
r=0.1168, p=0.491). ROC curve analyses for (B) miR-1246, (C) miR-183, and (D) miR-
183+miR-1246 combined score.  
ROC curves for discriminating between tumour and normal mucosa demonstrated 
an AUC of 0.7175 (72.5% sensitivity, 60.0% specificity) for miR-1246, and 0.7706 
(62.86% sensitivity, 85.71% specificity) for miR-183 (Figure 6 B & C). This suggests 
that expression levels of both miRNA have an ability to discriminate between 
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tumour and normal mucosa. Consequently, it was assessed if this ability was 
improved when values for both miRNA were added together. When combined, an 
AUC of 0.7943 (72.7% sensitivity, 72.3% specificity) was found (Figure 6 D), this 
was superior to either single miRNA. Combining miR-183 and miR-1246 was found 
to be additive in their capacity to discriminate between tumour tissue and normal 
colonic mucosa. 
3.4.2 CRC stage and tumour tissue miRNA expression 
To determine whether there was any increase in tumour miRNA expression with 
advancing stage we seperately examined miRNA expression levels in stage I and II 
subgroups. 
 
Mean Fold Change (±SD) 
 Stage I (n=9) Stage II (n=33) Total (n=42) 
miR-19a 1.104 (0.6285) 1.716 (1.698) 1.585 (1.547) 
miR-1246 19.45 (37.56) 175.14 (541.7) 147.9 (494.6) 
miR-23a 1.485 (0.98) 1.526 (1.612) 1.517 (1.488) 
miR-183 616.83 (1245) 126.56 (286.7)  210.6 (575.1) 
Table 5 - Mean Fold Change in tumour tissue expression of candidate miRNA by stage. 
Substantial differences are seen from stage I to stage II for both miR-1246 and miR-
183 (Table 4). For miR-183 overexpression was greatest at stage I, there was a trend 
towards a significant decrease in overexpression from stage I to II, but this was not 
statistically significant (p=0.056, unpaired t-test). miR-1246 did also not show any 
significant difference in mean fold expression between stages.  
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3.5 Plasma EV miRNA expression in CRC patients vs controls 
The second focus of the study was to examine expression of the candidate miRNA in 
plasma EVs. Although significant increases in expression in tumour tissue were seen 
for miR-183 and miR-1246, no detectable expression of these miRNA was observed 
below the cut-off CT value of 35 in plasma EV samples (n=18 for miR-183 and n=8 
for miR-1246). Both miR-23a and miR-19a, which demonstrated a trend towards an 
increase in expression in tumour tissue, were consistently expressed in plasma EVs.  
 
Figure 7 - miRNA expression in plasma EVs of controls and CRC patients (A) miR-19a 
(B) miR-23a. ** = <0.01, unpaired t-test,  note: reversed y-axis. 
miR-19a was significantly downregulated in the EVs of the CRC group compared to 
controls (p=0.0043; Figure 7 A). No difference was seen for miR-23a (Figure 7 B). 




3.5.1 Plasma EV miRNA expression in CRC patients by stage vs controls 
Examining differences in plasma EV miRNA dysregulation across stages may be 
useful to determine how early in CRC progression changes can be detected in the 
bloodstream of patients. 
 
Figure 8 - miRNA expression in plasma EVs by stage vs controls (A) miR-19a (B) miR-
23a. * = p<0.05, one-way ANOVA with Tukey post hoc analysis. Note: reversed y-axis. 
Significant differences in expression of miR-19a in plasma EVs were observed 
between each stage and controls (Figure 8 A). Subsequently, the mean fold change 
in plasma EV expression was also examined. For miR-19a, a 0.139 fold change (7.2 
fold decrease) in expression for stage I and 0.256 fold change (3.9 fold decrease) for 
stage II was observed. This suggests that downregulation of plasma EV miR-19a 
expression is greater at stage I than stage II; however, the differences in EV 




3.5.2 Association between plasma-EV miRNA and other blood-based markers 
To determine the ability of plasma EV miR-19a to act as a liquid biopsy and 
differentiate between early stage CRC patients and healthy controls, a ROC curve 
analysis was performed. This corresponded with an AUC of 0.6104 (sensitivity 62%, 
specificity 53%).  
As seen in the tissue analysis, two variables with independent expression may be 
added together to examine if it improves the ability to discriminate when combined. 
miR-19a demonstrated differential expression in plasma EVs. It was subsequently 
added to CEA, another blood based marker, which has a limited ability to identify 
CRC.  
No correlation was observed between miR-19a and CEA (Spearman’s r=-0.002, 
p=0.9852). Firstly, a ROC curve analysis was used for CEA alone to differentiate CRC 
and controls, which corresponded with an AUC of 0.6576 (sensitivity 45%, 
specificity 76%). Secondly, CEA was combined with miR-19a in another ROC curve 
analysis; however, when this was calculated the AUC declined to 0.5217 (sensitivity 
57%, specificity 50%), which was inferior to either marker individually. Therefore, 
it does not appear that CEA and miR-19a are additive in the context of a blood based 
diagnostic biomarker in CRC.  
Expression of EV miR-19a was correlated with other blood-based markers in CRC 
to assess if any relationship was observed. When using Spearman’s test, a negative 
correlation between miR-19a and NLR was seen (r=-0.308, p=0.011). This was 
mirrored by a negative correlation between miR-23a, which had not demonstrated 
any difference in plasma EV expression, and NLR (r=-0.2561, p=0.0411). No further 
correlations were observed between either circulating EV miRNA and other blood-




3.5.3 Association between plasma-EV and tissue expression 
Correlations between tumour tissue and plasma EV miRNA expression were 
examined to assess if differences in tumour tissue expression effected the levels in 
circulating EVs.  
 
Figure 9 - Correlation between ΔCT values for plasma EVs and tumour tissue (A)     
miR-19a (Spearman’s r=-0.1808, p=0.258). (B) miR-23a (Spearman’s r=0.0217, 
p=0.8927). n=41 x-y pairs. 
No correlation was observed between tumour tissue and plasma EVs (Figure 9 A). 
When subsequently comparing miRNA expression levels between tissue and EVs, 
there was a depletion in expression of miR-19a in EVs compared to tissue, with a 















Chapter 4: Discussion 
This study has examined miRNA dysregulation in tissue and plasma EVs from early 
stage CRC patients, in order to assess if these miRNA are suitable liquid biopsy 
biomarkers. Current stool-based screening methods for CRC are imperfect, due to 
both limited sensitivity for detecting early stage disease and sub-optimal patient 
participation (30, 32-34). If a blood-based test that was as effective, or superior to, 
current methods it would almost certainly increase diagnosis rates of early CRC 
leading to decreased healthcare costs and improved patient outcomes.  
CRC tumours release EVs into the bloodstream, miRNA within these EVs have 
shown significant potential as liquid biopsy biomarkers to help identify these 
patients. This study identified four candidate miRNA from the literature, all of which 
have demonstrated promise as biomarkers in CRC. However, these miRNA have 
never been examined together in a well-defined, early stage, cohort with matched 
tissue and plasma samples. 
Our first aim was to establish evidence of dysregulation of the four candidate 
miRNAs in tumour tissue when compared to matched normal colonic mucosa. Two 
of the four candidate miRNAs, miR-183 and miR-1246, were significantly elevated 
in CRC tumour tissue.  
Our second aim was to determine whether any dysregulation in tissue translated to 
altered expression in plasma EVs of stage I and II CRC patients compared to healthy 
controls. miR-183 and miR-1246 were overexpressed in tissue but were not reliably 
expressed in plasma EVs when using our methods. However, miR-19a was shown 
to be significantly downregulated in plasma EVs of CRC patients. A significant 
difference was even seen when comparing only stage I patients to controls, 
additionally it has superior sensitivity to CEA when identifying CRC; both of these 
factors suggest it may have potential as a liquid biopsy biomarker.  
There a number of issues that need to be addressed in the search for a liquid biopsy 
biomarker in CRC. There are benefits and disadvantages to various methods of EV 
isolation and results in miRNA analysis can vary greatly depending on the chosen 
method. Furthermore, whether candidate EV miRNA are initially identified from 
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dysregulation in tumour tissue, or instead concentrating solely on markers in the 
circulation, or even on a broader discovery-based approach may be most useful. 
This is the first study to examine these four proposed markers together in matched 
tumour tissue and plasma EV samples, and significant dysregulation between CRC 
and controls was observed. There are substantial challenges in the search for a 
liquid biopsy, however the benefits to doing so are clear and obvious. An effective 
liquid biopsy in CRC has the potential to greatly benefit the growing numbers of 





4.1 Patient Demographics 
There were no statistically significant differences in terms of age or gender between 
the CRC patient cohort and controls. When comparing the demographics of our 
cohort to CRC in the wider New Zealand population, the findings were broadly 
similar. In our study, the average age at diagnosis for colon cancer was 67.7 years 
and rectal cancer was 66.7 years. In the PIPER project, which is representative of a 
New Zealand population, the average ages for colon and rectal cancer were 67.9 and 
71.4 years respectively (12). In the PIPER project overall, 75% were diagnosed with 
colon cancer and 25% with rectal cancer. Our figures of 78.8% and 21.2% for the 
plasma EV analysis appear to be more in line with what has previously been 
reported in New Zealand (10, 12, 139).  
There were some notable differences between the tissue and plasma EV groups 
however. Only 11.9% of patients in the tissue analysis had rectal cancer, therefore 
our findings in tissue may not be directly applicable to rectal cancer. This is 
attributable to exclusion from the tissue analysis if a patient previously received 
neoadjuvant radiation. Neoadjuvant radiation has been demonstrated to alter the 
miRNA profile in CRC tissue (131); including both irradiated and non-irradiated 
CRC tumour in the same tissue analysis would introduce unknown confounding 
effects.  
Neoadjuvant treatment similarly had a bearing on patient selection in the plasma 
analysis. All plasma samples were collected at the initial clinic appointment 
following diagnosis, prior to any treatment. Staging in our study is based on 
pathological examination of the resected surgical specimen, although preoperative 
staging is also recorded. If any change in staging occurred following neoadjuvant 
treatment, these patients were excluded from the plasma analysis, as they may have 
had more advanced disease at the time of plasma collection. Fourteen patients with 
rectal cancer were excluded in this manner. Because neoadjuvant treatment is only 
given in rectal cancer, this may further explain the difference between the higher 
rates of rectal cancer in New Zealand, and in the biobank overall, compared to our 
plasma analysis cohort.  
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4.2 Endogenous reference gene miRNA 
For tissue, both miR-16 and miR-345 were used as endogenous reference genes, 
where there was no significant difference in expression between tumour tissue and 
normal mucosa. However, following analysis of our plasma EV data, miR-345 was 
not found to be suitable as an endogenous control. miR-345 has previously been 
recommended as a reference gene in CRC for both tissue and plasma EVs (133, 135). 
Danese et al. (2017) specifically endorses its use in the context of plasma EVs, this 
was following its successful use as a reference gene in CRC tissue by Chang et al. 
(133, 135). In the paper by Danese and colleagues, there is insufficient reporting of 
methodology, particularly the method of EV isolation, this may be a possible point 
of difference (135).  
There are some technical considerations with RT-qPCR when identifying suitable 
endogenous reference genes for plasma EVs. Equal volumes of plasma were used 
for every sample in an attempt to ensure consistency in the quantity of RNA 
processed. One option may have been to use an exogenous control that is ‘spiked in’ 
(36). This may have demonstrated more reliable expression than our endogenous 
reference genes. However, expression of exogenous controls is dependent on the 
quantity of RNA extracted and does not change with natural variations in miRNA 
expression in the same manner as an endogenous control (140). Additionally, other 
studies have used RNA, such as RNU6B and RNU5A, instead of miRNA as an 
endogenous control, however these may not reflect natural differences in miRNA 
expression as accurately as a miRNA reference gene (81, 85, 91). Furthermore, 
employing multiple endogenous reference genes may be superior to a single 
endogenous control (141). Finding suitable endogenous reference genes in this 
context is an acknowledged issue in the literature that remains a focus of ongoing 
investigation (135, 142). 
Any endogenous reference gene should ideally demonstrate reasonably high 
expression in order to ensure consistency across samples. Due to the nature of 
plasma EVs, the total RNA content that can be extracted is very low compared to 
tissue. This was exhibited in our data where the CT values of miRNA from plasma 
EVs were much higher (i.e. lower relative expression) across all miRNA when 
compared to tissue. For example, miR-16a was expressed in all samples in the study 
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with no difference between CRC and control groups in either the tissue or the 
plasma EV analysis. However, miR-16 demonstrated a 108-fold decrease in 
expression between tissue and plasma EVs (mean CT values 17.27 vs 24.04 across 
all tissue and plasma EV samples respectively). 
4.3 Tissue miRNA expression 
Of the four candidate miRNA, all were expressed in both tumour tissue and normal 
colonic mucosa. miR-183 and miR-1246 demonstrated significantly increased 
expression in tumour tissue, both miR-19a and miR-23a did not show any 
significant dysregulation.  
miR-1246 was found to have a 147.9 fold increase in expression in tumour tissue 
compared to normal mucosa. There are conflicting reports in the literature 
regarding its expression in tissue, where results have shown its expression to be 
both elevated and mildly decreased (90, 91). Findings of an overexpression of miR-
1246 in tissue is consistent with work produced by Scarpati et al. (2014), where a 
smaller 2.12 fold increase in expression from 54 CRC tumours, of which 24 were 
stage I and II (90). However, it conflicts with another study by Yamada and 
colleagues (2014) where a mild, 1.3 fold decrease expression was found in 33 
tumours, of which 13 were early stage (90). Sample processing may have affected 
the measured miRNA expression in the study by Yamada et al., as samples were 
frozen in liquid nitrogen. In contrast, in our study samples were immediately stored 
in RNAlater Stabilization Solution™, which may have improved RNA quality 
compared to freezing (143).  
Our results also demonstrated a significant overexpression of miR-183 in tumour 
tissue compared to normal mucosa. This is in line with the published data that 
consistently reports an increase in expression in tumour tissue (108, 109, 111). 
Both miR-1246 and miR-183 demonstrated an ability to discriminate between 
tumour tissue and normal mucosa on a ROC curve analysis. This may have limited 
applications in the search for a blood-based biomarker, but it is useful to evaluate 
the capacity of a marker in discriminating between CRC and control tissue and 
examine against other known variables. Where ROC curve analysis offers greatest 
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benefit in the context of our research is when it is used to compare CRC patients to 
healthy controls on a blood-based test, to assess potential as a liquid biopsy. 
There was no correlation between miR-183 and miR-1246, suggesting that 
expression of each miRNA was independent of one another. It is important to ensure 
that no correlation exists prior to combining variables in a ROC curve (144, 145). If 
expression of each variable is related then combining them may lead to a spurious 
inflation of predictive capabilities (144, 145).  A combined ROC curve found the 
discriminatory powers of both miRNA together was better than either miRNA alone. 
Both miRNA were subsequently evaluated for relationships with, demographic, 
blood-based (CEA, CRP, NLR) and pathological (PNI, EMVI, LVI, MMR) variables, but 
no direct correlations were found. However, when dichotomised into high (≥2 fold 
change) and normal miR-1246 (<2 fold change) expression groups, an association 
between high miR-1246 expression and increased NLR, a prognostic marker in CRC 
was observed. miR-1246 has been shown to be significantly elevated in metastatic 
compared to primary CRC tissue, and to promote tumour growth and metastasis in 
in-vitro models (146, 147). It has not been specifically identified as a prognostic 
marker to date in the literature; however its association with metastatic CRC 
suggests a possible relationship with advanced disease. 
Interestingly, for both miR-1246 and miR-183 there was a significant association 
with female gender and the high miRNA expression group on chi-squared tests. The 
significance of this is uncertain, however it should be taken into consideration for 
any further research regarding these miRNA. Gender differences and ethnic 
variations in miRNA expression have been documented (148, 149). Differences in 
miRNA expression between demographic variables are an important consideration, 
both for interpreting published data, and in developing any miRNA based 
biomarkers. It is possible that different liquid biopsy biomarkers may perform 
significantly better in a specific group and ongoing research in this field should take 
this into account. It is possible that certain miRNA biomarkers will be more specific 
depending on gender or ethnicity. One solution may be developing specific miRNA 
biomarkers for these demographic variables. Another strategy may to combine a 
number of miRNA biomarkers together in a panel that may mitigate against some of 
these inconsistencies in expression. 
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Our results demonstrated a trend towards an overexpression of miR-19a in tumour 
tissue when compared to normal mucosa, this trend disappeared following 
exclusion of a single outlier from each of the tumour and normal colonic tissue 
groups. Data comparing miR-19a from early stage CRC tissue to matched normal 
mucosa does not appear to have been published in the current literature. It has been 
shown to be upregulated in tissue samples from CRC liver metastasis when 
compared to stage I and II primary CRC tumours (85). Our data did not evaluate 
metastases, but no statistically significant changes in expression were observed 
between either stage I or II and controls. If it is associated with metastatic CRC, 
tissue miR-19a may have potential as a prognostic biomarker. Patients who 
overexpress miR-19a in tissue may have worse outcomes such as higher recurrence 
rates. Of note, elevated levels of serum EV miR-19a have previously been associated 
various adverse factors such as LVI, metastatic disease, resistance to chemotherapy 
and worse overall survival (85, 99). An interesting area of future research would be 
to evaluate both tissue miR-19a and miR-1246 as prognostic biomarkers. A 
limitation of our cohort is that no 5-year follow up data is currently available to 
examine this. 
In our study, there was no significant differences in miR-23a expression between 
normal mucosa and tumour. This conflicts with the published literature where miR-
23a has been demonstrated to be elevated at least two-fold in tumour compared to 
normal colonic tissue in a number of studies (100-102). These studies did not 
specifically identify stage I or II patients in the data and elevated levels of miR-23a 
that are reported may be due to more advanced stage III and IV CRC. This would not 
have been detected in our study.  
Tumour miRNA expression of the four candidate liquid biopsy biomarkers was 
examined in order to establish if changes in CRC tissue translated to changes in 
plasma EVs. It is possible that there is selective packaging of specific miRNA from 
tissue into EVs but this was not observed in our data. EV miRNA dysregulation in 
CRC may also not originate in tumour tissue, but from some other source, such as 
immune cells, red blood cells or platelets. Due to this, we must question the 
paradigm of initial miRNA analysis in tumour tissue to identify dysregulation 
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translating to circulating EVs, if the goal is to develop a blood-based liquid biopsy 
biomarker.  
4.4 Plasma EV miRNA expression 
Two of the four candidate miRNA were expressed consistently in plasma EVs of 
early stage CRC patients and healthy controls, of these miR-19a demonstrated a 
significant decrease in expression. miR-183 and miR-1246, both of which exhibited 
significant increases in tumour tissue, were not reliably expressed in plasma EVs 
when using our methods. 
Our results found a 4.6 fold decrease in plasma EV miR-19a between healthy 
controls and CRC patients. In the literature, miR-19a was found to be dysregulated 
in circulating EVs (85, 99). Interestingly, this study found the direction of 
dysregulation was opposite to our findings. Matsumara et al. (2015) found an 
increase in miR-19a expression in serum EVs from 107 stage I and II CRC patients, 
compared to 28 healthy controls, a population which is broadly similar to our cohort 
(85). In light of this noteworthy difference between our findings and the currently 
available literature, further evaluation of miR-19a in circulating EVs is warranted, 
especially as plasma EV miR-19a may have potential as a liquid biopsy biomarker in 
early stage CRC.  
miR-19a demonstrated significant differences for both stage I and II when 
compared to healthy controls on a one-way ANOVA test. The earlier in disease 
progression changes are detected in the bloodstream of patients, the greater 
potential a biomarker may have as a liquid biopsy. A detectable difference in stage I 
disease is ideal if developing a liquid biopsy for screening. It aids in identifying 
patients at the earliest stage of disease, which requires less intensive treatment and 
has improved long-term outcomes. When examining mean changes in expression, 
no significant differences were found. However, the mean fold change in expression 
was greatest at stage I (0.139, 7.2 fold decrease) in comparison to stage II (0.265, 
3.9 fold decrease). Examining plasma EV expression of miR-19a in more advanced 
stages of CRC may be beneficial to assess if there are any significant differences in 
expression with further CRC progression. 
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When the expression levels between tumour and plasma EVs were compared, miR-
19a was found to be depleted in plasma EVs compared to tumour tissue. This 
corresponded with a 0.192 fold change in expression (5.2 fold decrease). However, 
no significant change in miR-19a tumour expression was found on tissue analysis. 
A trend towards an increase in tumour tissue was observed, that was not 
statistically significant (p=0.0579). It is possible that this is reflecting miR-19a 
sequestration in tumour tissue and our study population (n=42) was underpowered 
to detect this difference. The directionality of a decrease in EVs, with a possible 
trend towards an increase in tumour tissue is interesting and may benefit from 
further examination. 
Another possibility is that miR-19a containing EVs are sequestered at a specific site 
in the body in CRC. EVs have been shown to localise to pre-metastatic niche sites in 
the liver (150). If EVs were to concentrate in the liver, or possibly the lymphatic 
system, they may demonstrate decreased levels of expression when sampled from 
the circulation. It is also conceivable that miR-19a in circulating EVs originates in 
another source from CRC tissue entirely such as immune cells, and it is the body’s 
response to CRC that effects EV miRNA expression. The exact cause for 
downregulation of EV miR-19a is unclear and requires further investigation. 
CEA is the only currently used blood-based marker in CRC. It is used to monitor for 
recurrence, but is not used in the diagnostic or screening setting due to limited 
sensitivity and specificity (38). It is possible that if CEA was combined with another 
biomarker, that had a similar capacity to identify CRC, their ability to detect CRC 
would be additive. Combining two markers may then reach the appropriate levels 
of sensitivity and specificity to be useful as a liquid biopsy. The ability of plasma EV 
miR-19a to act as a liquid biopsy and differentiate between early stage CRC and 
healthy controls was evaluated. Plasma EV miR-19a had better sensitivity but lower 
specificity than CEA (sensitivity 62% and 45%, specificity 53% and 76% for miR-
19a and CEA respectively). A high sensitivity is very beneficial when attempting to 
develop a screening test, and the fact that miR-19a has been shown to outperform 
CEA is promising. However, when compared against FIT (sensitivity 79%, specificity 
94%), it appears that substantial progress is required. When the AUC of either 
marker was compared, CEA was superior. However, when combined together, they 
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were inferior to either individual marker when it came to differentiating stage early 
stage CRC patients from healthy controls.  
Plasma EV miR-19a was compared against a number of currently available blood-
based markers, there was a significant negative correlation between miR-19a and 
NLR, a prognostic marker. As plasma EV miR-19a is decreased in CRC, a negative 
correlation implies that both change in opposite directions in the presence of CRC. 
Previous research has found an elevation of serum EV miR-19a to be associated with 
a number of poor prognostic indicators including LVI, metastatic disease, and 
resistance to chemotherapy (85, 99). This increase in expression conflicts with the 
decrease observed in our data. It is possible that miR-19a may have an association 
with advanced disease, although the directionality of change in our data conflicts 
with published literature. A weakness in our study cohort is that no long-term 
follow up is currently available. Assessing both plasma EV miR-19a and tissue miR-
1246, where an association with NLR was similarly seen, as prognostic indicators in 
our cohort in the future may provide further insight into any potential prognostic 
applications of these miRNA. 
miR-1246 was not consistently expressed in plasma EVs when using our methods, 
despite a number of published studies documenting overexpression in circulating 
EVs in CRC (81, 85, 86, 90). As miR-1246 expression levels were significantly 
elevated in tissue, it is possible that it is being sequestered by CRC cells and thus not 
present in EVs at detectable levels. The current literature suggests a promising 
blood-based EV biomarker that is overexpressed in early stage CRC. Previous 
studies have reported a significant capacity to differentiate patients of all stages 
from healthy controls with an AUC of 0.948, and a sensitivity of 90% was found 
when discriminating stage I CRC from controls in a smaller validation cohort (86). 
Although our results did not demonstrate reliable expression in EVs, it warrants 
ongoing attention as a possible liquid biopsy biomarker. 
Similarly to miR-1246, miR-183 exhibited a significant increase in expression in 
tumour tissue that did not translate to the plasma-EV analysis. Two studies that 
demonstrated miR-183 elevation in tissue also found that it was elevated in whole 
plasma. EVs were not isolated in these studies and it is possible that it was freely 
circulating, rather than EV, miR-183 that was detected (87, 110). miR-183 is part of 
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a miRNA family which includes miR-182 and miR-96, it has been suggested that 
miR-182 is preferentially packaged over miR-183 into EVs. It has been documented 
that miR-182 was the only detectable member of the miR-183 family in EVs from 
multiple breast and prostate cancer cell lines and it is possible that a similar process 
occurs in CRC (151).  
miR-23a was expressed from all 66 plasma EV samples, but no difference in 
expression was found between early stage CRC and healthy controls. Plasma and 
serum EV levels have previously been shown to be upregulated in stage I and II CRC 
when compared to healthy controls and to decrease post resection (36, 85, 86). 
Ogata-Kawata and colleagues (2014) found miR-23a was able differentiate stage I 
CRC from healthy controls with an AUC of 0.953, this varies substantially from our 
findings (86). A common theme across all of the miRNA, in both tissue and plasma 
EVs is an inconsistency between our findings and the published literature. A number 
of possible explanations have been suggested and a significant area of variance 
across studies may lie in methodological differences. 
4.5 Methodological differences 
There are numerous differences in pre-analytical variables that are not consistent 
with our methods, including EV isolation and control selection. Analysing these 
areas of variance may offer insight into the discrepancies between our results and 
the published literature.  
Our chosen method of EV isolation was SEC columns. Advantages of this method 
include its ease of use, low levels of co-isolated impurities and that it can be 
automated to adapt to the higher throughputs required in a commercial laboratory 
(152). None of the referenced studies used SEC columns or an automated fraction 
collector (AFC), which is a significant difference from our research. An AFC offers 
significant efficiency benefits and can process approximately six samples an hour. 
Multiples of this can be processed by a single person if more than one machine is 
available. In our study, two machines were used, this allowed EVs to be extracted 
from approximately twelve samples an hour. For any liquid biopsy to become a 
clinically viable test, adopting methods that can readily be applied to a commercial 
laboratory is an important challenge to address.  
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One of the most common methods of EV isolation employed in the literature is 
ultracentrifugation (UC). It has been used as the sole method of isolation, as density 
gradient UC, or in conjunction with filtration (81, 85, 86). UC is limited by the 
number of samples, typically six, that can be processed at a time. In addition, it can 
take 18 hours or more to process a set of samples (81). Low-density lipoproteins 
outnumber EVs in the circulation. SEC has shown significantly less co-isolation of 
soluble proteins when compared to UC (152). SEC-based EV isolation is an effective 
method of removing these high-abundance blood-based proteins, however this 
increased purity is sacrificed for decreased EV yield (153).  
Different EV isolation methods have demonstrated significant variance in the 
quantity and quality of EV-specific miRNA, in addition to the amount of co-isolated 
impurities such as proteins, when analysing the same set of samples across different 
isolation methods (154, 155). It is possible that in studies where UC was employed, 
a significant amount of the miRNA expression was coming from non-EV sources 
such as freely circulating miRNA. This may offer an explanation as to why some of 
our results are significantly different to what has been reported. For example, high 
levels of expression of circulating EV miR-1246 are described in the literature but it 
was not reliably expressed when using our methods (86).  
With regard to serum or plasma, there is conflicting evidence as to which source 
produces a higher miRNA yield from EVs (156, 157). Wang et al. (2012) found that 
serum produced a greater quantity of EV miRNA, whereas McDonald and colleagues 
(2011) reported that the opposite to be the case (156, 157). A majority of referenced 
studies used serum; this may offer another significant point of difference that may 
explain inconsistencies between our results and the reported data. Furthermore, 
contamination of a sample due to haemolysis, platelets or other impurities may also 
contribute to varying miRNA expression findings (156, 158, 159). To control for this 
in our study, all blood collection and plasma processing was standardised. All 
samples were visually inspected for haemolysis both at the time of processing and 
prior to EV isolation; in addition, pre-clearing centrifugation of thawed plasma 
samples was performed to reduce impurities. 
Control selection may also be a contributing factor. It is possible that many ‘healthy 
controls’ may have underlying adenoma, CRC or inflammatory bowel disease that 
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can only be revealed by colonoscopy. In the NBSP pilot study, 51.5% of those who 
underwent colonoscopy had adenomatous polyps (35). The majority of studies in 
the literature did not state whether control patients had a normal colonoscopy to 
rule out these abnormalities prior to recruitment; this is a significant difference to 
our methods of control recruitment. It is conceivable that a significant proportion 
of controls in the current literature had underlying colonic adenoma, which may 
have a significant, but unknown effect on miRNA expression. 
4.6 Strengths and limitations 
The samples size of our cohort is a limiting factor. Although our research was 
adequately powered to detect differences in the primary aims, there were a number 
of additional areas that demonstrated trends in the data that our study was not 
powered to detect. There was greater than twice the amount of CRC patients 
compared to controls, were more controls available we may have been able to 
observe a significant decrease in the expression levels of miR-19a, rather than only 
in ΔCT values. A trend towards an increase of miR-19a in tissue was also observed, 
however this did not reach the threshold for significance. In light of the significant 
decrease of EV miR-19a in plasma, confirming overexpression in tissue by 
increasing the number of tissue samples analysed, would suggest that CRC tumour 
tissue is sequestering miR-19a and not releasing it into EVs. 
The use of a single reference gene in the analysis of plasma EVs is another weakness, 
miR-345 demonstrated inconsistent expression and only miR-16 was used. Ideally, 
at least two reference genes should be used (141). Additionally, using the same two 
endogenous reference genes across all tissue and plasma EV samples would have 
ensured greater consistency in the study, as this is a point of difference between the 
tissue and EV analysis. 
A limitation of the study is the relatively low proportion of rectal cancers compared 
to colon cancers in the tissue analysis. Due to the nature of rectal cancer treatment, 
up to 70% of patients will receive neoadjuvant radiotherapy alone or with 
chemotherapy (160). These patients were excluded from the study as neoadjuvant 
treatment may cause changes in tissue miRNA expression (131). Recent evidence 
suggests that the proportion of rectal cancers, as a total of CRC, is increasing (161). 
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Only 11.9% of patients in the tissue analysis had rectal cancer, this does not 
represent the current, nor the likely future landscape of CRC. Therefore, caution 
should be exercised in interpreting the tissue findings as they are predominantly 
related to colon cancer.  
A further question that requires attention is whether our approach in choosing 
candidates from the literature is the most effective strategy to identify a blood-
based biomarker. The use of EV miRNA as biomarkers is a rapidly developing field. 
The advantage of using an EV isolation method such as SEC is a lack of 
contamination; this is especially useful when candidate markers have been 
identified. However, at this early stage of EV miRNA research there is a possibility 
that it is overly selective. Employing a discovery-based method in the form of small 
RNA sequencing, which is able to measure all small RNA species in an unbiased 
fashion may be more useful for identifying novel biomarkers in CRC that may be 
missed with SEC. 
Quek et al. (2017) states that co-isolated impurities in EV isolation have little 
bearing on downstream miRNA quantification and that efficient, but more crude EV 
isolation strategies may be more useful for biomarker discovery (162). Specific 
methods that purify EVs above all other cell-free material, such as SEC may result in 
smaller libraries and worse performance when clustering is performed (154). 
Buschmann et al. (2018) found that EV isolation by methods such as precipitation, 
yields samples with decreased purity and significant co-isolated protein 
contamination, but states that these methods may have more potential for 
biomarker discovery (154). Our candidate-based approach has the potential to 
overlook markers that may be well suited to being a liquid biopsy in CRC.  
Although there may be benefits to these methods, what makes EV related miRNA 
attractive as biomarkers is their potential specificity for diseases such as CRC. As 
previously discussed, CRC cells produce an abundance of EVs compared to normal 
cells, and the contents of EVs directly reflect their parent cell of origin. The literature 
has suggested that miRNA profiles between CRC and controls, in tissue and EVs, to 
be significantly different. The potential for EV miRNA to be sensitive and specific for 
CRC is substantial. There are many sources of miRNA within the bloodstream, 
including red blood cells, platelets and free miRNA. Less EV-selective methods may 
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analyse miRNA from a host of sources, which may defeat the purpose of isolating 
EVs. Future work may examine differences between whole plasma and EVs with 
regard to developing liquid biopsies. 
Additionally, our research has found that matched tumour tissue and plasma EV 
samples can differ significantly in miRNA expression. It is not clear whether 
circulating EV miRNA dysregulation in CRC is originating from tumour tissue, or 
from another source entirely such as platelets, red blood cells or immune cells. If the 
ultimate goal is to develop a liquid biopsy for CRC, solely concentrating on markers 
that are dysregulated in the blood stream of CRC patients, rather than starting with 
tissue, may prove more beneficial. miRNA analysis in tissue may be more suited to 
identification of a prognostic biomarker in CRC, miRNA expression levels in tissue 
are much higher, in addition EVs do not require isolation. Identifying tissue miRNA 
that give insight into prognosis may have a substantial role to play in decision 
making regarding adjuvant treatment and intensity of post-operative follow up. 
A strength of the study lies in the standardisation and automation of EVs from 
plasma using SEC columns and the AFC. Prior to the introduction of the AFC, this 
process involved manually collecting drops from the SEC column, this process may 
be inaccurate and user dependent. Another advantage is that this method has ease 
of scalability to meet the demands of a hospital laboratory, an important 
consideration for any liquid biopsy to become commercially viable.  
Our recruitment identified age and sex matched controls that were symptomatic in 
the form of abdominal pain, perirectal bleeding or other symptoms suggestive of 
CRC but did not have disease on colonoscopy. This ensures that our controls are a 
cohort patients who would be most likely avail of a liquid biopsy test for CRC were 
it to become available. As these patients were recruited from endoscopy lists, it was 
necessary to consent prior to the procedure. Sedation is usually given during a 
colonoscopy and patients would be unable to give consent afterwards. Of the 53 
patients recruited in this fashion, less than half were eligible controls and most of 
the remainder had polyps. Disadvantages of this method include the significant time 




This approach also had benefits however; collecting samples from a subset of 
patients with known polyps to the CRC biobank has potential for future research. 
Adenomatous polyps are the initial stage in the adenoma-carcinoma sequence 
(163). Up to 51% of patients who undergo a colonoscopy looking for CRC will have 
polyps, as evidenced in the NBSP pilot study (35). Circulating EV miRNA 
dysregulation has been reported to commence once a polyp is formed (164, 165). It 
will be possible to compare healthy control, polyp and CRC subgroups to further 
assess the effect polyps have on plasma EV miRNA expression.  A liquid biopsy that 
can identify polyps prior to developing into CRC has obvious benefits. Furthermore, 
control patients used in this study can be used across a range of CRC research that 
is conducted in the SCRG.  
4.7 Future directions 
There are a number of challenges in developing EV miRNA as liquid biopsies in CRC. 
Much research has focused on total circulating, rather than EV-specific, miRNA 
levels. An advantage of this strategy is that there is no requirement for EV isolation, 
this has efficiency benefits with regard to sample processing, but potentially has 
lower specificity for CRC. It is also apparent that all the miRNA discussed are 
dysregulated in multiple disease processes, in addition to possible changes in 
expression across demographic variables such as gender or ethnicity. Combining a 
number of miRNA together in a panel may be a useful way to offset this lack of 
specificity. 
It is not currently obvious how to best identify candidate EV miRNA biomarkers. It 
is possible a discovery based approach may detect novel markers which have the 
required sensitivity and specificity for a liquid biopsy. If this approach is taken, then 
consideration of the EV isolation methods is necessary as SEC may be overly 
selective. Additionally, as changes in tissue miRNA expression do not appear to have 
a predictable effect on EV miRNA expression, the utility of tumour tissue analysis in 
the search for a liquid biopsy for diagnostic or screening purposes should be 
questioned.  
The literature may be inconsistent in part due to differences in pre-analytical 
variables and there appears to be insufficient reporting of methodology in some 
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cases. There is a need to standardize methods and develop technologies that aid in 
the isolation and detection of EVs to make it practical to perform in a hospital 
laboratory. Our methods are possibly a step closer to becoming clinically feasible, 
as the capacity to process samples can readily be increased. Global adoption of the 
MISEV 2018 guidelines across EV research may be a useful starting point to address 
some of these methodological issues (166).  
It is necessary to evaluate how EV miRNA liquid biopsy biomarkers can be 
integrated into a modern healthcare system. Ideally, a blood-based biomarker 
would outperform current faecal-based assays on all parameters for screening. 
Identifying EV miRNA biomarkers that are both sensitive and specific to CRC may 
prove challenging. Using biomarkers in conjunction with current screening 
methods may provide an alternative avenue for their adoption to current clinical 
practice. Implementing blood-based screening in the first instance, followed by a 
stool-based test if suggestive of CRC is one option. Another possible route is 
performing the liquid biopsy following a negative faecal-based assay in the context 





New Zealand has some of the highest rates of CRC in the world, but it is also a 
growing global issue. Current strategies to diagnose CRC, such as population level 
stool-based screening, are flawed. If a blood based screening test for CRC was 
available, it would have substantial benefits including an improvement in patient 
outcomes. EV associated miRNA appear to have great potential as liquid biopsy 
biomarkers in CRC that may help address this. Our study examined four miRNAs in 
both tissue and plasma EVs based on promising data in the literature.  
Plasma EV miR-19a was significantly downregulated in EVs of CRC patients. It 
demonstrated significant differences even when stage I patients alone were 
compared against controls, it also had superior sensitivity to CEA in our cohort. 
These factors are promising in the context of developing a liquid biopsy marker to 
screen for CRC. However, its specificity was poor and it requires further 
examination to establish any efficacy. 
Questions remain over the initial analysis of miRNA dysregulation in tissue in order 
to observe translation to EVs. Our results did not demonstrate any relationship 
between EVs and tissue. The benefits of tissue analysis may lie in developing 
prognostic biomarkers that can help in post-surgical treatment planning. 
Additionally, considering the current evolving landscape of EV miRNA biomarker 
research, whether a selective candidate-based approach or a more broad discovery-
based approach are the most effective methods of identifying potential markers 
remains to be seen.   
Plasma EV miRNA display great promise as liquid biopsy biomarkers, but currently 
there are a number of challenges in identifying a marker specific for CRC. Finding a 
liquid biopsy biomarker for CRC that is as effective, or outperforms, current stool-
based screening methods may lead to significant increases in screening 
participation rates. The subsequent effects would likely include increased rates of 
diagnosis of early CRC, with decreased healthcare costs and improved clinical 





Stage T N M 
0 Tis N0 M0 
I T1/T2 N0 M0 
II T3/T4a/T4b N0 M0 
III T1/T2/T3/T4 N1a/b/c/N2a/b/c M0 
IV Any T Any N M1a/M1b 
Table S1 – Colorectal Cancer TNM Staging (AJCC 7th edition) Tis = carcinoma in situ, 
T1 = tumour invades submucosa, T2 = tumour invades muscularis propria, T3 = 
tumour invades into pericolorectal tissues T4 = tumour penetrates to the surface of 
the (a) visceral peritoneum or (b) directly invades, or is adherent to other organs or 
structures, N0 = No regional lymph node metastasis, N1 = Metastasis in 1-3 lymph 
nodes (a= 1, b= 2-3, c = no lymph nodes but deposits in subserosa, mesentery or non-
peritonalised perirectal/mesorectal tissues,, N2 = metastasis in 4 or more regional 
lymph nodes (a = 4-6, b = 7+). M0 = no distant metastasis, M1 = Distant metastasis (a 





 Normal Mucosa (mg) Tumour Tissue (mg) 
 18.8 48.9 
 65.3 68 
 45.9 28 
 33.8 12.6 
 38.7 58 
 36.8 16.6 
 19.2 36.8 
 33.2 36.8 
 26.2 36.1 
 40.5 55.2 
 17.8 21.7 
 41.4 10.6 
 24.8 6.5 
 29.2 9.5 
 66.6 32.6 
 32 19.2 
 47.8 24.8 
 36.1 46.7 
 78.2 64.3 
 53.3 66.4 
 15.2 10.7 
 19.5 14.1 
 31.3 54.3 




36.09 (16.89) 33.64 (19.87) 
Table S2 – Values for weight of matched tissue used in analysis (n=24).  
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 Normal Mucosa (ng/uL) Tumour Tissue (ng/uL) 
 51.7 1884.7 
 666.2 302.4 
 1465.2 620.9 
 3281 5074.7 
 1323.9 938.5 
 2121.8 895.7 
 75.1 4825.5 
 665.9 473.1 
 82.3 288.8 
 337.4 702.6 
 226.1 446.1 
 1239.9 1307.7 
 808.3 1260.3 
 1486.7 2072.6 
 252.8 623.8 
 1501.5 728.9 
 459.7 190.4 
 308.3 145.1 
 575.1 790.5 
 164.3 1093.5 
 153 696.8 
 451.2 238.5 
 313.5 128.1 
 278 1249.4 
 319.1 489 
 1177.2 1115 
 155.1 580.2 
 1388 1521.8 
 1092.8 794.4 
 422.5 1492.5 
 125.7 481 
 1158.5 1735.7 
 353.3 1887.5 
 1694.3 2627.1 
 388.2 220.3 
 140.9 185.3 
 450.2 598.7 
 257.7 989.2 
 666.8 168.7 
 430.5 455.9 
 608.7 1355 
 3854 1266 
   
Mean 
Conc. 
(SD) 702.5 (663.5) 1070 (1059) 




 Mean fold change in expression (±SD) 
 miR-19a miR-23a miR-183 miR-1246 
EMVI Present (n=3) 0.67 (0.19) 0.86 (0.45) 11.47 (18.57) 18.28 (7.19) 
EMVI Absent (n=39) 1.65 (1.58) 1.57 (1.53) 1165 (3356) 197.2 (561) 
p value 0.296 0.437 0.567 0.589 
LVI Present (n=4) 1.51 (1.14) 0.35 (0.11) 1.08 (0.59) 80.15 (130) 
LVI Absent (n=38) 1.59 (1.59) 1.64 (1.51) 1105 (3272) 195.1 (569.4) 
p value 0.925 0.100 0.646 0.693 
dMMR (n=9) 1.32 (0.84) 1.05 (0.63) 27.24 (17.86) 394 (890) 
pMMR (n=33) 1.65 (1.69) 1.64 (1.63) 1229 (3448) 114.8 (366) 
p value 0.578 0.296 0.502 0.180 
PNI Present (n=3) 0.68 (0.19) 0.86 (0.44) 11.47 (18.57) 18.28 (7.19) 
PNI Absent (n=39) 1.65 (1.58) 1.57 (1.53) 11.47 (18.57) 197 (561) 
p value 0.296 0.434 0.567 0.589 
Female (n=19) 1.68 (1.88) 1.95 (1.92) 445.5 (951) 355 (766) 
Male (n=23) 1.50 (1.24) 1.15 (0.89) 1740 (4694) 36.17 (84.36) 
p value 0.719 0.082 0.360 0.726 
Left sided CRC (n=17) 1.6 (1.67) 1.67 (1.75) 438 (885) 279 (699) 
Right sided CRC (n=25) 1.56 (1.38) 1.28 (1.00) 2123 (5346) 55.9 (129) 
p value 0.941 0.411 0.254 0.217 
 Correlations (Spearman’s rank coefficient) 
Age (Spearman’s r) 0.019 -0.055 -0.143 -0.159 
p value 0.905 0.727 0.534 0.347 
Table S4 - mean fold changes in tumour tissue expression and clinical and pathological 
















EMVI Present  1 0 1 0 
EMVI Absent  10 24 13 26 
p value  0.257  0.350 
LVI Present  2 2 2 1 
LVI Absent  9 22 12 25 
p value  0.575  0.2763 
dMMR  3 5 4 4 
pMMR  8 19 10 22 
p value  0.685  0.4162 
PNI Present  1 1 2 1 
PNI Absent  10 23 12 25 
p value  0.536  0.2763 
Female  2 14 2 16 
Male  9 10 12 10 
p value  0.035  0.007 
Left sided CRC  6 8 7 10 
Right sided CRC  5 16 7 16 
p value  0.283  0.521 
Stage I  2 4 4 3 
Stage II  9 20 10 23 
P value  0.999  0.214 
Table S5 – High and low tumour tissue expression subgroups for miR-183 and miR-1246 
with relationships to clinical and pathological variables. Chi-squared test for all. 
















Age (mean ±SD) 71.55 (11.76) 66.58 (13.94) 70.14 (12.52) 66.65 (12.61) 
p value  0.3136  0.4079 
CEA (mean ±SD) 3.96 (6.31) 5.63 (6.57) 4.04 (5.75) 5.13 (6.37) 
p value  0.4867  0.5977 
CRP (mean ±SD) 7.7 (5.14) 10.96 (20.89) 15.92 (26.72) 9.15 (9.49) 
p value  0.6322  0.2513 
NLR (mean ±SD) 3.01 (1.35) 2.85 (1.14) 2.45 (0.86) 3.21 (1.22) 
p value  0.700  0.0444 
Table S6 - High and low tumour tissue expression subgroups for miR-183 and miR-1246 





 miR-19a miR-23a 
CEA 0.034 0.019 
p value 0.793 0.875 
CRP -0.157 -045 
p value 0.242 0.721 
NLR -0.276 -0.308 
p value 0.032 0.011 
Table S7 – Correlations of plasma EV miRNA expression and blood-based variables. 
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